KITS COMPRISING UNIT-DOSE ORAL TREATMENT COMPOSITIONS

Abstract

Kits comprising unit-dose oral treatment compositions. The present invention relates to kits comprising unit-dose oral treatment compositions with two or more flavorings. Kits comprising unit-dose oral treatment compositions with two or more beneficial agents. An oral treatment regimen comprising applying water to a toothbrush and collecting a unit-dose oral treatment composition without the consumer having to handle the unit-dose oral treatment composition.

Description

1 / 83 KITS COMPRISING UNIT-DOSE ORAL TREATMENT COMPOSITIONS FIELD OF THE INVENTION

[0001] The present invention relates to unit-dose oral treatment compositions. The present invention relates to kits comprising a unit-dose oral treatment composition comprising a first flavoring agent and a unit-dose oral treatment composition comprising a second flavoring agent. The present invention also relates to kits comprising a first unit-dose oral treatment composition comprising a first beneficial agent and a second unit-dose oral treatment composition comprising a second beneficial agent. BACKGROUND OF THE INVENTION

[0002] Toothpaste compositions are typically formulated as a paste that can be squeezed out of a tube. Toothpaste compositions may include a fluoride agent, abrasives, calcium sources, surfactants, bleaching agents, humectants, thickening agents, and other formulation ingredients. Typically, toothpaste compositions need to be carefully formulated to avoid reactivity in the tube but retain reactivity in the oral cavity.

[0003] Since toothpaste compositions are commonly formulated as a paste, it is not economical to sell multiple flavorings or multiple formulations within a single kit. Consequently, there is a need for single-dose oral care compositions that can allow consumers Petition 870210111416, dated 01 / 12 / 2021, page 7 / 104 2 / 83 select multiple beneficial agents or multiple flavorings without the consumer having to store multiple tubes. SUMMARY OF THE INVENTION

[0004] Disclosed in the present invention is a kit comprising: (a) a first unit-dose oral treatment composition comprising a first flavoring and (b) a second unit-dose oral treatment composition comprising a second flavoring, wherein the first flavoring is not equivalent to the second flavoring.

[0005] Also disclosed in the present invention is a kit comprising: (a) a first unit-dose oral treatment composition comprising a first benefit agent and (b) a second unit-dose oral treatment composition comprising a second benefit agent, wherein the first benefit agent is not equivalent to the second benefit agent.

[0006] Also disclosed in the present invention is a scheme for oral treatment comprising (a) adding water to a toothbrush, (b) collecting a first unit-dose oral treatment composition with the toothbrush and (c) applying the first unit-dose oral treatment composition to an oral cavity. BRIEF DESCRIPTION OF THE FIGURES

[0007] Figure 1 is a photograph of a moistened toothbrush collecting a unit-dose oral treatment composition. Petition 870210111416, dated 01 / 12 / 2021, page 8 / 104 3 / 83

[0008] Figure 2 is a photograph of the moistened toothbrush beginning to dissolve the unit-dose oral treatment composition.

[0009] Figure 3 is a photograph of the moistened toothbrush beginning to dissolve the unit-dose oral treatment composition.

[0010] Figure 4 is a photograph of the moistened toothbrush beginning to dissolve the unit-dose oral treatment composition while in an upright position.

[0011] Figure 5 is a photograph of a side view of a secondary container for the unit dose oral treatment composition.

[0012] Figure 6 is a photograph of a front view of a secondary container for the unit dose oral treatment composition. DETAILED DESCRIPTION OF THE INVENTION

[0013] The present invention relates to oral treatment compositions that are unit-dose oral treatment compositions. The use of a unit-dose oral treatment composition, such as a unit-dose toothpaste composition, can provide a composition with an exact dosage, as opposed to the consumer having to estimate the appropriate dose.

[0014] Additionally, due to the use of unit-dose compositions, the kits may comprise multiple flavorings, beneficial agents, etc. The use of kits comprising two or more unit-dose oral treatment compositions may allow for better Petition 870210111416, dated 01 / 12 / 2021, page 9 / 104 4 / 83 results of oral health, flavor customization, benefit customization, etc. Definitions

[0015] To define more clearly the terms used in the present invention, the following definitions are provided. Except where indicated otherwise, the following definitions are applicable to this disclosure. If a term is used in this disclosure but is not specifically defined herein, the definition from the IUPAC Compendium of Terminology, Chemistry, 2nd edition (1997) may be used, provided that such definition does not conflict with any other disclosure or definition applied herein, or render undefined or impossible any claim to which such definition applies.

[0016] The term oral treatment composition, as used herein, means a product that, in the course of normal use, is retained in the oral cavity for a sufficient time to come into contact with some or all of the dental surfaces and / or oral tissues for oral health purposes. In one embodiment, the composition is retained in the oral cavity to release an active agent for oral treatment. The oral composition of the present invention may be in various forms, including toothpaste, dentifrice, dental gel, dental powders, tablets, mouthwash, subgingival gel, foam, mousse, chewing gum, lipstick, sponge, dental floss, prophylactic paste, petrolatum gel, denture product, nonwoven fabric, or foam. In one embodiment, the oral composition exists in the form of a nonwoven fabric. In another embodiment, the oral composition exists in the form of a dentifrice. Petition 870210111416, dated 01 / 12 / 2021, page 10 / 104 5 / 83 Oral composition may also be incorporated into strips or films for direct application or fixation to oral surfaces or incorporated into dental floss. The oral treatment composition may also be a strip that can be directly applied to a surface of the oral cavity. The strip may at least partially dissolve upon contact with moisture or brushing.

[0017] The term acceptable oral vehicle, as used in the present invention, refers to a suitable ingredient or vehicle that can be used to form and / or apply the present compositions in the oral cavity in a safe and effective manner.

[0018] The term effective amount, as used in the present invention, refers to an amount of a compound or composition sufficient to induce a positive benefit, or an oral health benefit, and / or an amount low enough to avoid serious side effects, that is, to provide an adequate benefit-risk ratio, within the good judgment of one skilled in the art. Depending on the type of oral health benefit and the efficacy of the active compound, effective amount means at least about 0.0001% of the material, 0.001% of the material, or 0.01 of the material, by weight of the composition.

[0019] The term dentifrice, as used herein, means paste, gel, powder, tablets or liquid formulations, unless otherwise specified, that are used to clean, treat or come into contact with the surfaces of the oral cavity. Additionally, as disclosed herein, dentifrice means a non-stick coating. Petition 870210111416, dated 01 / 12 / 2021, page 11 / 104 6 / 83 tissue that is used to clean the surfaces of the oral cavity. The term teeth, as used in the present invention, refers to natural teeth as well as artificial teeth or dental prostheses.

[0020] As used herein, the term filament means a filamentous, flexible, thin object that can be used to form a nonwoven mat of the present type. The length of a filament may greatly exceed its diameter, that is, a length-to-diameter ratio of at least about 5, 10, or 25.

[0021] The filaments of the present invention can be spun from nonwoven blanket-forming materials by means of suitable spinning operations, such as melt-blown spinning or continuous spinning.

[0022] Filaments are typically considered to be continuous or substantially continuous in nature. Filaments are relatively longer than fibers. Non-limiting examples of filaments may include meltblown filaments, continuous spinning filaments, and combinations thereof. In one embodiment, the filaments are meltblown filaments.

[0023] In one example, the filaments may be in the form of fibers, such as when the filaments are cut into shorter lengths. Thus, in one example, the present invention also includes a fiber comprising the filament composition of the present invention.

[0024] As used herein, nonwoven blanket-forming material means a composition that is suitable for manufacturing a filament such as through blow spinning, Petition 870210111416, dated 01 / 12 / 2021, page 12 / 104 7 / 83 Continuous spinning, or fluid film fibrillation. The nonwoven blanket-forming material comprises one or more nonwoven blanket-forming materials that exhibit properties that make them suitable for spinning into a filament.

[0025] As used herein, length with respect to a filament means the length along the filament's major geometric axis from one end to the other end. If a filament has a knot, a curl, or bends, then the length consists of the length along the entire path of the filament.

[0026] As used herein, average diameter, with respect to a filament, is measured in accordance with the Diameter Test Method described herein.

[0027] As used herein, the term disintegrable and disintegration means that the oral treatment composition, filament, or nonwoven fabric is reduced to components, fragments, or compositions when exposed to the intended conditions of use.

[0028] As used herein, the term dissolve means that the mouthwash composition, filament, or nonwoven mat is largely or completely solubilized. The mouthwash composition may appear to dissolve visibly even if some of the components do not dissolve completely—for example, cross-linked polyacrylic acid polymers form transparent gels giving the appearance of dissolution while, without adhering to theory, the transparent gels are simply hydrated. Another example is an abrasive that does not dissolve at all even though it may comprise the majority of the Petition 870210111416, dated 01 / 12 / 2021, page 13 / 104 8 / 83 composition. An oral composition comprising an abrasive would still be considered to be dissolved if only the abrasive has not dissolved. Dissolution of the oral treatment composition is complete when any remaining particles have a diameter of 2 mm or less.

[0029] As used herein, the term apply includes spraying, powder splattering, spraying, coating, surface printing (e.g., in the form of a desired ornament, decoration or pattern), pouring on, injection into, immersion, or by any other suitable means, such as by the use of a depositor, sieve, or powder bed.

[0030] As used herein, intended conditions of use means the temperature, physical, chemical and / or mechanical conditions to which an oral treatment composition comprising one or more filaments of the present invention is exposed when the oral treatment composition is used for its intended purpose. The oral treatment compositions of the present invention may be administered to a mammal via the oral cavity, mouth, throat and combinations thereof. The intended conditions of use may be the temperature, physical, chemical and / or mechanical conditions in the oral cavity, mouth, and / or throat of a mammal.

[0031] Triggering condition, as used herein, means anything, such as an action or event, that serves as a stimulus and initiates or causes a change in the filament, such as a loss or alteration of the filament's physical structure and / or a release of an active ingredient for oral treatment including dissolution, hydration and Petition 870210111416, dated 01 / 12 / 2021, page 14 / 104 9 / 83 swelling. Some triggering conditions include proper pH, temperature, shear rate, or water content.

[0032] Morphological changes, as used herein, with respect to a change in filament morphology means that the filament exhibits an alteration in its physical structure. Some non-limiting examples of morphological changes for a filament of the present invention include dissolution, melting, swelling, shrinkage, breaking into pieces, extension, shortening, displacement, grinding, implosion, twisting, and combinations thereof. The filaments of the present invention may completely or substantially lose their filament physical structure or may have their morphology altered or may retain or substantially retain their filament physical structure as they are exposed to intended use conditions.

[0033] As used herein, a blanket means a sheet of continuous filaments or fibers of any nature or origin that have been formed into a blanket by any means, and joined together by any means.

[0034] As used herein and as defined by the European Disposables and Nonwovens Association (EDANA), nonwoven fabric means a sheet of continuous filaments or fibers of any nature or origin that have been formed into a mat by any means and bonded together by any means, with the exception of weaving or knitting. Felts obtained by wet milling are not nonwovens. In one example, a nonwoven fabric according to the present invention means an ordered arrangement of filaments within a structure for Petition 870210111416, dated 01 / 12 / 2021, p. 15 / 104 10 / 83 perform a function. In one example, a nonwoven blanket of the present invention is an arrangement comprising a plurality of two or more and / or three or more filaments that are intertwined or otherwise associated with each other to form a nonwoven blanket.

[0035] The term RDA refers to Relative Dentin Abrasion or Radioactive Dentin Abrasion, as defined in FDI-ISO 11609. The term PCR refers to Pellicle Cleaning Ratio, as defined in the original document by Stookey et al. 1982 and subsequently used by Schemehorn et al. 2011 to characterize the relative effectiveness of oral treatment compositions in removing a laboratory-derived, human-like stain from enamel chips. These experimental techniques will be described in greater detail later.

[0036] All percentages and ratios used below are by weight of the total composition, except where otherwise indicated. All percentages, ratios and ingredient contents referred to herein are based on the actual amount of the ingredient and do not include solvents, fillers or other materials with which the ingredient may be combined as a commercially available product, except where otherwise indicated. All measurements mentioned herein are carried out at 25°C, except where otherwise indicated.

[0037] The composition, process and methods of the present invention may comprise, consist of or consist essentially of the essential elements and limitations of the invention described herein, as well as any Petition 870210111416, dated 01 / 12 / 2021, p. 16 / 104 11 / 83 additional or optional ingredients, components or limitations described herein or otherwise useful in oral treatment compositions intended for use or consumption by mammals, preferably for consumption or use by humans. Unit-dose oral treatment composition

[0038] The oral treatment compositions of the present invention may be unit-dose oral treatment compositions. A unit-dose oral treatment composition is an amount of the oral treatment composition to be administered to a patient or consumer in a single use. The unit-dose oral treatment composition may be a unit-dose toothpaste, a unit-dose mouthwash, a unit-dose dental gel, a unit-dose teeth whitening composition, or any other suitable unit-dose oral treatment composition capable of being retained in the oral cavity for a sufficient time to come into contact with some or all of the dental surfaces and / or oral tissues for oral health purposes.

[0039] The quantity, by mass and / or volume, of the unit-dose oral treatment composition is determined based on the desired type of unit-dose oral treatment composition. For example, a unit-dose toothpaste may be sized to deliver the correct amount of fluoride in a single use in accordance with local laws and regulations, such as the US Food and Drug Administration (FDA) monograph, which allows formulations of 850 to 1150 ppm and / or 1500 ppm of fluoride ions. Additionally, a unit-dose toothpaste Petition 870210111416, dated 01 / 12 / 2021, page 17 / 104 A 12 / 83 unit dose can be sized to release the correct amount or ratio of other ingredients, such as antimicrobial agents, abrasives, surfactants, flavorings, metal ions, etc. Similarly, a unit dose mouthwash can be sized to release the correct amount of mouthwash ingredients, such as fluoride ions, antimicrobial agents, abrasives, surfactants, flavorings, metal ions, etc.

[0040] The unit-dose oral treatment composition may be in the form of a containment bag, a droplet, a solid open-cell foam, a solid closed-cell foam, a fibrous composition, a paste composition, a gel composition, a tablet composition, a strip composition, a tape composition, and / or a combination of one or more of the forms described in this paragraph.

[0041] The unit-dose oral treatment composition may be sized to fit a manual toothbrush, an electric toothbrush, or any other applicator designed to help the unit-dose oral treatment composition come into contact with the surfaces of the oral cavity, including, but not limited to, teeth.

[0042] The unit-dose oral treatment composition of the present invention may be a flat or substantially flat composition in the form of a block, strip, ribbon or tablet having a thickness of about 0.05 mm to about 20 mm, about 0.05 mm to about 10 mm, about 0.05 mm to about 5 mm, about 0.5 mm to about Petition 870210111416, dated 01 / 12 / 2021, p. 18 / 104 13 / 83 mm, from about 0.05 mm to about 0.5 mm, from about 0.05 mm to about 0.25 mm, or from about 0.05 mm to about 0.1 mm, as measured by the Thickness Method described herein. The unit-dose oral treatment composition may be formed in a cylindrical shape (e.g., by rolling) having a length of about 0.5 centimeters (cm) to about 10 cm, from about 1 cm to about 5 cm, or from about 1.5 cm to about 3 cm. The unit-dose oral treatment composition may be a rectangular prism including a cube with the longer sides of the rectangular prism having a length of about 5 mm to 20 mm, from about 10 mm to 15 mm, or from about 5 mm to about 10 mm, as measured by the Thickness Method described herein. If the dose dimensions change, the base dose weight may change.The unit-dose oral treatment composition may be circular or oval, with the diameter of the circle or the length of the longest portion of the oval being approximately 5 mm to approximately 5 cm, 5 mm to approximately 100 mm, 5 mm to approximately 50 mm, 1 cm to approximately 5 cm, or 100 mm to approximately 1 cm.

[0043] The unit-dose oral treatment composition may be in the form of one or more sheets or flat blocks of a size suitable for easy handling by the user. The unit-dose oral treatment composition may comprise a unit dose of one or more oral treatment actives that may provide one or more oral treatment benefits and / or treat one or more oral treatment conditions. The unit-dose oral treatment composition may have a square, rectangular, oval, circular, or disc shape. Petition 870210111416, dated 01 / 12 / 2021, page 19 / 104 14 / 83 or any other suitable format. The unit-dose oral treatment composition may also be in the form of a continuous strip including release by a tape-like cylinder dispenser with individual portions dispensed through perforations and / or a cutting mechanism.

[0044] A unit-dose oral treatment composition may allow the dose to include incompatible components in the same composition. Components are considered incompatible with each other if, when they are in the same solution or as non-solid mixtures, at least one of the components has a significant reduction in efficacy, stability, or bioavailability. Incompatible components may be components that chemically interact with each other to form new compounds, complexes, and / or salts, and / or components that will separate into distinct portions or phases of the composition to minimize unfavorable interactions.

[0045] Examples of incompatible components may include, but are not limited to, metal ion sources and silica-based abrasives, metal ion sources and polyphosphates, metal ion sources and pyrophosphates, calcium ion sources and fluoride ion sources, calcium ion sources and phosphate salts, calcium ion sources and pyrophosphate, oxalate ions and peroxide compounds, peroxide-based compounds and stannous fluoride, cationic antimicrobial agents such as cetylpyridinium chloride and fluoride ion sources, acids and bases, calcium ion sources and chelating agents such as EDTA, oxidizing agents and agents Petition 870210111416, dated 01 / 12 / 2021, page 20 / 104 15 / 83 reducing agents, hydrophobic components such as petrolatum, silicone, polybutene and hydrophilic components such as water and alcohols, and / or any other incompatible components as defined above.

[0046] Unit-dose oral treatment compositions, as described herein, can be designed to maximize the bioavailability, stability, and / or efficacy of the ingredients by minimizing reactivity between the ingredients. Minimizing reactivity between ingredients can be achieved by physically separating the ingredients into distinct portions of the composition or by placing one or more ingredients in the solid phase where reactivity is lower.

[0047] In the context of a containment bag composition, the internal volume can be separated into multiple distinct, layered, adjacent and / or overlapping portions that can place one or more components in each portion. For example, a fluoride ion source may be in one portion while a calcium ion source may be in another portion of the containment bag composition. Additionally, a metal ion source may be in one portion while a silica- or polyphosphate-based abrasive may be in another portion of the containment bag composition.

[0048] In the context of a fibrous oral treatment composition, one or more reactive components may be in one layer of nonwoven mat and one or more reactive components may be in another layer of nonwoven mat. Additionally, one or more components Petition 870210111416, dated 01 / 12 / 2021, page 21 / 104 16 / 83 Reactive components may be in one or more layers of nonwoven fabric, and one or more reactive components may be between, on top of, below, folded within, adjacent to, or superimposed on one or more layers of nonwoven fabric, as in a non-fibrous composition. For example, a fluoride ion source may be spun within or mixed with a first fibrous composition comprising one or more layers of nonwoven fabric, and a calcium ion source may be spun within or mixed with a second fibrous composition comprising one or more layers of nonwoven fabric. The first and second fibrous compositions may be assembled into a single multi-layered composition using any suitable means.Additionally, a fluoride ion source may be spun within or mixed with a fibrous composition comprising one or more layers of nonwoven mat, and a calcium ion source may be in a non-fibrous composition, either as a solid composition or at least partially dissolved or at least partially dispersed in a liquid composition. The fibrous composition and the non-fibrous composition may be assembled into a multi-layered composition, or the non-fibrous composition may be between, on top of, below, folded within, adjacent to, or superimposed on the fibrous composition.

[0049] In the context of a foam oral treatment composition, as a porous, flexible, dissolvable solid structure, the reactive components may be within or mixed together within an open-cell or closed-cell foam; foam compositions are described in US 2011 / 0027328, which is incorporated herein by reference. One or more components Petition 870210111416, dated 01 / 12 / 2021, page 22 / 104 17 / 83 Reactive components may be in the foam composition, while one or more reactive components may be in a non-foam composition, such as a surface-resident particulate coating that coats the surface of the solid foam composition.

[0050] The use of a unit-dose oral care composition, as described herein, allows for easy portability and the ability to better control dosage. For example, due to current airline restrictions on liquid products, a passenger is limited to carrying only a small amount of mouthwash or toothpaste or packing their mouthwash or toothpaste in their checked baggage. If the oral care composition were in unit-dose form, the passenger could pack exactly the amount needed in a carry-on bag without having to worry about airline packing restrictions. Composition for the treatment of fibrous oral conditions.

[0051] The oral treatment composition may be a fibrous oral treatment composition. The fibrous oral treatment composition may comprise a fibrous composition and / or a non-fibrous composition. The fibrous composition may comprise at least one mat. The fibrous composition may comprise a non-woven mat and / or a woven mat.

[0052] The fibrous composition may comprise one or more layers of mat. The one or more layers of mat may comprise one or more filaments and / or fibers. The composition for oral treatment may comprise a first mat and Petition 870210111416, dated 01 / 12 / 2021, page 23 / 104 18 / 83 a second blanket, wherein the first and second blankets comprise different components.

[0053] The fibrous composition may comprise any component for suitable oral treatment. The fibrous composition may comprise any component described herein.

[0054] The blanket may comprise more than one filament. The blanket may comprise a first filament and a second filament, both comprising an oral treatment active ingredient, and the oral treatment active ingredient may be the same oral treatment active ingredient or different oral treatment active ingredients. The blanket may comprise a first filament comprising an immediate-release oral treatment active ingredient and a second filament comprising a prolonged-release, delayed-release, and / or targeted oral treatment active ingredient. The blanket may comprise a first filament, a second filament, and a third filament, each filament comprising a different oral treatment component.

[0055] The oral treatment pad or composition may comprise a plurality of identical or substantially identical filaments from a compositional perspective according to the present invention. The oral treatment pad or composition may comprise two or more different filaments according to the present invention. Some non-limiting examples of differences in the filaments may be physical differences such as differences in diameter, length, texture, shape, stiffness, elasticity and the like; chemical differences such as level of Petition 870210111416, dated 01 / 12 / 2021, page 24 / 104 19 / 83 crosslinking, solubility, melting point, glass transition temperature (Tg), coating material, color, amount of oral treatment active ingredient, amount of coating material, presence of a coating composition over the oral treatment composition, chemical composition of the oral treatment active ingredient including whether the oral treatment active ingredient is for immediate application, delayed application, prolonged application, or targeted application, and the like; differences in whether the filament loses its physical structure when the filament is exposed to the intended conditions of use; differences in whether the filament morphology changes when the filament is exposed to the intended conditions of use; and differences in when and where the benefit of the oral treatment active ingredient is perceived.In one example, two or more filaments within the oral treatment composition or mat may comprise the same mat-forming material but have different oral treatment actives.

[0056] The blanket may comprise two or more filaments, with the filaments applying the oral treatment actives at different rates. The different rates may be caused by the filaments being positioned on an outer surface of the blanket.

[0057] The oral treatment composition may comprise a non-fibrous composition, which may or may not be a greater percentage by weight of the oral treatment composition than the fibrous composition. The non-fibrous composition may be between a first layer and a second layer. At least a portion of the non-fibrous composition may be in contact with a surface of Petition 870210111416, dated 01 / 12 / 2021, page 25 / 104 20 / 83 fibrous composition. The non-fibrous composition can be placed in a single layer of mat and the mat layer can be folded over the non-fibrous composition, rolled with the non-fibrous composition, placed on top of or below the fibrous composition and / or the fibrous composition can wrap around the fibrous composition.

[0058] The non-fibrous composition may comprise any component suitable for oral treatment. The non-fibrous composition may comprise any component described herein. The non-fibrous composition may be liquid, solid, aqueous and / or combinations thereof.

[0059] The oral treatment composition of the present invention may have a base weight of about 10 grams per square meter (g / m2) to about 5000 g / m2, from about 25 g / m2 to about 2500 g / m2, from about 40 g / m2 to about 1500 g / m2, or from about 500 g / m2 to about 2000 g / m2.

[0060] The fibrous oral treatment composition may comprise two or more oral treatment components or actives that are generally considered incompatible, as described herein. For example, a first layer of mat may comprise a fluoride ion source and a second layer of mat may comprise a calcium ion source. In another example, a first layer of mat may comprise a metal ion source, such as a stannous ion source, and a non-fibrous composition may comprise a silica-based abrasive or a polyphosphate.

[0061] The oral treatment blanket or composition may exhibit different regions, such as different regions of Petition 870210111416, dated 01 / 12 / 2021, page 26 / 104 21 / 83 base weight, density and / or gauge. The oral treatment composition or blanket may comprise distinct filament regions that differ from other parts of the blanket.

[0062] A mouthwash composition or mat may comprise one or more surfaces having a textured pattern, a wavy pattern, or otherwise a topographically pattern including letters, logos, or figures. The textured mouthwash composition may result from the shape of the filament or mat, whereby the outermost surface of the composition contains portions that are raised relative to other areas of the surface. The raised portions may result from the shape formed of the mouthwash composition, for example, the mat may be formed in a wavy or waffle pattern. The raised portions may also be the result of crimping processes, printed coatings, embossing patterns, or the result of the physical shape of the composition itself.

[0063] The mat of the present invention can be compressed into a film to form the oral treatment composition; this can be done by applying a compressive force and / or heating the mat to convert the mat into a film. The film may comprise the oral treatment actives that were present in the filaments of the present invention. The mat may be completely converted into a film or parts of the mat may remain in film form after partial conversion of the mat into the film. The oral treatment composition may consist of one or more mats, at least one of which has been compressed into a film. Petition 870210111416, dated 01 / 12 / 2021, page 27 / 104 22 / 83 composition for oral treatment may comprise two or more pads that have been compressed into a film.

[0064] The blanket can be rolled, compressed, cut, or stacked to form a three-dimensional oral treatment composition. For example, the blanket can be compressed into a pill or tablet, rolled into a cylinder, or compressed or stacked into a rectangular prism to form the oral treatment composition.

[0065] The oral treatment composition may consist of one or more layers of mats that are optionally bonded to each other by means of a bonding means (including heat, moisture, ultrasonic, pressure, etc.). The oral treatment composition may consist of one or more layers of mats that are optionally bonded to each other by means of compression.

[0066] The oral treatment composition or nonwoven mat may be perforated with holes or channels penetrating into or through the oral treatment composition, either wholly or locally in one or more layers of mat. These perforations may be formed as part of the manufacture of the mat or oral treatment composition by means of spikes extending from the surface of a conveyor belt, drum, cylinder or other adjacent surface. Alternatively, these perforations may be formed after forming the mat or oral treatment composition by a process of pricking or piercing the porous solids with pins, needles or other sharp objects. Petition 870210111416, dated 01 / 12 / 2021, page 28 / 104 23 / 83 Filament

[0067] The oral treatment composition may comprise one or more filaments. In one embodiment, the filaments of the present invention exhibit a length greater than about 0.1 in., in an alternative embodiment greater than about 0.2 in., in yet another embodiment greater than about 0.3 in., and in another embodiment greater than about 2 in.

[0068] Filaments may have an average diameter less than about 150 micrometers (µm), less than about 100 µm, less than about 10 µm, or less than about 1 µm with a relative standard deviation less than 100%, less than 80%, less than 60%, or less than 50%, such as in the range of 10% to 50%, for example. As described herein, the significant number means at least 10% of all filaments, in another embodiment at least 25% of all filaments, in another embodiment at least 50% of all filaments, in yet another embodiment at least 75% of all filaments. The significant number may be at least 99% of all filaments. At least 50% of all filaments may have an average diameter less than about 10 µm. The filaments produced by the method of the present disclosure may have a significant number of filaments with an average diameter smaller than about 1 µm, or sub-micron filaments.In one embodiment, the composition for oral treatment may comprise at least 25% of all filaments with an average diameter less than about 1 µm, at least 35% of all filaments with an average diameter less than about 1 µm, or at least 50% of all filaments with an average diameter less than about 1 µm. Petition 870210111416, dated 01 / 12 / 2021, page 29 / 104 24 / 83 at least 75% of all filaments with an average diameter smaller than about 1 μm.

[0069] The filament may comprise less than 30% moisture by weight of the filament, less than 20% moisture by weight of the filament, less than about 10% moisture by weight of the filament, less than about 5% moisture by weight of the filament, less than about 3% by weight of the filament, less than about 1%, or less than about 0.1% by weight of the filament.

[0070] The filament of the present invention can be single-component or multi-component. The filament can be a two-component filament. The filament can be a three-component filament. The multi-component filament can be in any form, such as side-by-side, core and sheath, sea islands and the like.

[0071] The filaments of the present invention may be meltblown filaments. The filaments of the present invention may be continuous spinning filaments. The filaments may be hollow filaments before and / or after the release of one or more of their active agents.

[0072] The filament may comprise an oral treatment active within the filament and an oral treatment active on an external surface of the filament, such as a coating on the filament. The oral treatment active on the external surface of the filament may be the same as or different from the active agent present in the filament. If different, the oral treatment actives may be compatible or incompatible with each other. Petition 870210111416, dated 01 / 12 / 2021, page 30 / 104 25 / 83 Solid foam compositions

[0073] The oral treatment composition may be a solid foam composition, such as the porous, flexible, dissolving solid structure described in US 2011 / 0027328, which is incorporated herein by reference. The solid foam composition may be in the form of an open-cell foam or a closed-cell foam.

[0074] The solid foam composition may comprise any component suitable for oral treatment. The solid foam composition may comprise any component described herein. The solid foam composition may comprise a surface-resident coating composition. The surface-resident coating composition may comprise any component suitable for oral treatment or any component described herein.

[0075] Importantly, US Patent Application No. 2011 / 0027328 does not disclose, teach, or suggest that the amount of pyrophosphate needs to be minimized to produce solid soluble foams. In fact, US Patent Application No. 2011 / 0027328 only teaches example foam compositions with a high amount of pyrophosphate. As such, it was unexpectedly discovered here that pyrophosphate interfered with the foam composition formation process.

[0076] Thus, the solid foam compositions of the present invention comprise a foaming material, one or more surfactants, a plasticizer, and wherein the solid foam composition has less than about 5%, less than about 1%, or is free of Petition 870210111416, dated 01 / 12 / 2021, page 31 / 104 26 / 83 of an inorganic metallic salt, a polyphosphate, or specifically, a pyrophosphate. The foaming material is any suitable material that exhibits properties suitable for making a foam. Non-limiting examples of foaming materials may include the water-soluble polymer disclosed by US patent application No. 2011 / 0027328. Blanket-forming material

[0077] The blanket may be formed by any suitable means. The blanket may comprise spun fibers and / or spun filaments. The nonwoven blanket may be made of a blanket-forming material or nonwoven blanket-forming material as described in U.S. Patent Application No. 16 / 250,455, U.S. Patent Application No. 16 / 250,484, U.S. Patent No. 9,139,802, U.S. Patent No. 9,175,250, and / or U.S. Patent No. 8,785,361, which are incorporated herein by reference in their entirety.

[0078] The mat-forming material may comprise any suitable material that exhibits suitable properties for making a filament or fiber. Non-limiting examples of mat-forming materials may include polymers, polyols, sugars, sugar alcohols, and combinations thereof. The mat may comprise two or more different mat-forming materials. The mat may comprise three or more different mat-forming materials. The polymer may function as a mat-forming material and in certain embodiments may also provide an oral health benefit.

[0079] The fibrous composition may comprise from about 1% to about 100%, from about 2% to about Petition 870210111416, dated 01 / 12 / 2021, page 32 / 104 27 / 83 50%, from about 5% to about 35%, from about 5% to about 20%, from about 1% to about 15%, or from about 5% to about 10% of a nonwoven blanket-forming material, by weight of the fibrous composition.

[0080] The oral treatment composition may comprise from about 1% to about 80%, from about 1% to about 50%, from about 1% to about 25%, from about 2% to about 20%, from about 3% to about 15%, less than about 10%, or from about 5% to about 10% of a mat-forming material by total weight of the oral treatment composition. Polymer

[0081] The oral treatment composition may comprise a polymer. The mat-formed material may comprise a polymer. The fibrous composition or the non-fibrous composition may comprise a polymer. The foam composition may comprise a polymer. Non-limiting examples of polymers may include naturally sourced polymers, synthetic polymers, and combinations thereof.

[0082] Non-limiting examples of polymers of natural origin may include alginates, gums, protein-based polymers, starch-based polymers, native starches, modified starches, fiber polymers, other polymers of natural origin, and combinations thereof.

[0083] Non-limiting examples of alginates may include ammonium alginate, calcium alginate, potassium alginate, propylene glycol alginate, and combinations thereof. Petition 870210111416, dated 01 / 12 / 2021, page 33 / 104 28 / 83

[0084] Non-limiting examples of gums may include acacia gum, carrageenan, tragacanth gum, guar gum, locust bean gum, xanthan gum, gellan gum, and combinations thereof.

[0085] Non-limiting examples of protein-based polymers may include whey protein isolate, soy protein isolate, egg albumin, casein, collagen, glutelin, gelatin, gluten, zein, and combinations thereof.

[0086] Non-limiting examples of starch-based polymers may include those starch-based polymers obtained from cereals, tubers, roots, legumes, fruits, and combinations thereof. Starch-based polymers may include glucose monomers linked by an α 1,4 linkage, amylose, amylopectin, and combinations thereof.

[0087] Non-limiting examples of native starches may include waxy or high-amylase maize varieties, peas, potatoes, bananas, barley, wheat, rice, sago, amaranth, tapioca, arrowroot, sugarcane, sorghum, and combinations thereof.

[0088] Non-limiting examples of modified starches may include hydroxypropyl starch, maltodextrin, high-amylose starch, and combinations thereof.

[0089] Non-imitating examples of fiber polymers may include pectins, fructo-oligosaccharides, inulin, agar, beta glucans, dextrins, lignin, celluloses, non-starch polysaccharides, reduced starch, Petition 870210111416, dated 01 / 12 / 2021, page 34 / 104 29 / 83 polycarbophil, citrus fiber and combinations thereof.

[0090] Non-limiting examples of other polymers of natural origin may include agar, pullulan, chitin, chitosan, shellac, and combinations thereof.

[0091] Non-limiting examples of synthetic polymers may include cellulose derivatives, carbomers, polymethacrylates, other synthetic polymers, and combinations thereof.

[0092] Non-limiting examples of cellulose derivatives may include hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl ethyl cellulose, methylcellulose, hydroxypropyl methylcellulose, and combinations thereof.

[0093] Non-limiting examples of carbomers may include carbomer 934, carbomer 934P, carbomer 940, carbomer 94, carbomer 1342, carbomer copolymers, carbomer homopolymers, carbomer interpolymers, and combinations thereof. Some carbomers are commercially available as Carbopol®934P NF polymer, Carbopol 971P NF polymer, and Carbopol®974P NF polymer.

[0094] Non-limiting examples of polymethacrylates may include ammonium methacrylate copolymer, basic butylated methacrylate copolymer, methyl methacrylate-methacrylic acid copolymer (1:1), ethyl acrylate-methacrylic acid copolymer (1:1), ethyl acrylate-methacrylic acid copolymer (1:2), 30% polyacrylate dispersion, methacrylic acid copolymer, amino methacrylate copolymer, methacrylate Petition 870210111416, dated 01 / 12 / 2021, page 35 / 104 30 / 83 ammonium, ammonium methacrylate copolymer dispersion, methyl methacrylate and ethyl acrylate copolymer, and combinations thereof. Some polymethacrylates are commercially available as Eudragit® E 12.5, Eudragit® E 100, Eudragit® E PO, Eudragit® L 12.5 P, Eudragit® L 12.5, Eudragit® L 100, Eudragit® L 100-55, Eudragit® L 30 D-55, Eudragit® S 12.5 P, Eudragit® S 12.5, Eudragit® S 100, Eudragit® FS 30 D, Eudragit® RL 12.5, Eudragit® RL 100, Eudragit® RL PO, Eudragit® RL 30 D, Eudragit® RS 12.5, Eudragit® RS 100, Eudragit® RS PO, Eudragit® RS 30 D, Eudragit® NE 30 D, Eudragit® NE 40 D, Eudragit® NM 30 D, Eastacryl™ 30 D, Kollicoat® MAE 30 DP, Kollicoat® MAE 100 P, Acryl-EZE®, Acryl-EZE® 93 A and Acryl-EZE® MP.

[0095] Non-limiting examples of other synthetic polymers may include poly(vinyl alcohol), carboxyvinyl polymers, polyvinylpyrrolidones, poly(ethylene oxide), polyoxyethylene and combinations thereof.

[0096] The polymer of the present invention may be selected such that its weight-average molecular weight is from about 20,000 Daltons (Da) to about 10,000,000 Da, from about 100,000 Da to about 5,000,000 Da, from about 500,000 Da to about 4,000,000 Da, or from about 1,000,000 Da to about 3,000,000 Da. The weight-average molecular weight is computed by summing the weight-average molecular weight of each raw material of the nonwoven fabric forming material multiplied by their respective percentages by weight relative to the weight of the total weight of polymers present within the filament. Petition 870210111416, dated 01 / 12 / 2021, page 36 / 104 31 / 83

[0097] The polymer can be poly(vinyl alcohol) with a weight-average molecular weight of about 10,000 Da to about 250,000 Da, in another embodiment of about 15,000 Da to about 200,000 Da and, in another embodiment, of about 20,000 Da to about 150,000 Da.

[0098] Poly(vinyl alcohol) can have a degree of hydrolysis of about 60% to 100%, about 65% to about 85%, less than 85%, about 70% to about 80%, or about 65% to about 95%.

[0099] The polymer may be selected from the group consisting of alginates, starch-based polymers, native starches, modified starches and combinations thereof with a weight-average molecular weight of about 1,000,000 Da to about 6,000,000 Da, about 1,500,000 Da to about 5,000,000 Da, or about 2,000,000 Da to about 4,000,000 Da.

[0100] The polymer may be selected from the group consisting of poly(vinyl alcohol), pullulan, pectin, corn starch, modified corn starch, hydroxypropyl methyl cellulose and combinations thereof.

[0101] The fibrous composition may comprise from about 0.1% to about 50%, from about 5% to about 40%, from about 15% to about 35%, from about 20% to about 30% or from about 15% to about 30% of a polymer by weight of the fibrous composition.

[0102] The non-fibrous composition may comprise from about 0.1% to about 50%, from about 5% to about 40%, from about 15% to about 35%, from about 20% to about 30% or from about 15% to about 30% of a polymer by weight Petition 870210111416, dated 01 / 12 / 2021, p. 37 / 104 32 / 83 of the non-fibrous composition or of the composition for oral treatment. Plasticizer

[0103] The oral treatment composition may comprise a plasticizer. Non-limiting examples of plasticizers may include polyols, polycarboxylic acids, polyesters, other suitable plasticizers and combinations thereof.

[0104] Non-limiting examples of polycarboxylic acids may include citric acid, succinic acid, and combinations thereof.

[0105] Non-limiting examples of polyesters may include glyceryl triacetate, diethyl phthalate, triethyl citrate, tributyl citrate, acetyl triethyl citrate, acetyl tributyl citrate and combinations thereof.

[0106] Non-limiting examples of other suitable plasticizers of the present invention include, but are not limited to, alkyl and allyl phthalates; lactates (e.g., sodium, ammonium, and potassium salts); lactic acid; soluble collagen; modified protein; monosodium L-glutamate; proteins and amino acids, such as glutamic acid, aspartic acid, and lysine; hydrogenated starch hydrolysates; other low molecular weight esters (e.g., C2-C10 alcohol and acid esters); and any plasticizer known to those skilled in the art in the food, dietary supplement, and pharmaceutical industries; and combinations thereof. Petition 870210111416, dated 01 / 12 / 2021, p. 38 / 104 33 / 83 Polyol

[0107] The oral treatment composition may comprise a polyol. The fibrous composition or the non-fibrous composition may comprise a polyol. The sheet-forming material may comprise a polyol. The foam-forming material may comprise a polyol. A polyol is an organic compound with more than one hydroxyl functional group. The polyol may comprise a sugar alcohol, a non-reducing sugar, a monosaccharide, a disaccharide, a polysaccharide and / or combinations thereof.

[0108] Sugar alcohols are a class of polyols that can be obtained by hydrogenating sugar compounds with the formula (CHOH)nH2, preferably where n=2-6. Suitable sugar alcohols include ethylene glycol, glycerin, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, volemitol, isomalt, maltitol, lactitol, maltotriitol, maltotetraitol and / or polyglycitol.

[0109] Non-reducing sugars are a class of saccharides that do not generate any compounds containing an aldehyde functional group. Non-reducing sugars are stable in water and do not react with weak oxidizing agents to produce sugar alcohols.

[0110] Non-limiting examples of monosaccharides may include glucose, fructose, and combinations thereof.

[0111] Non-limiting examples of disaccharides may include sucrose, maltose, lactose, high-fructose corn syrup solids, trehalose, cellobiose, gentiobiose, isomaltose, cojibiose, Petition 870210111416, dated 01 / 12 / 2021, page 39 / 104 34 / 83 laminaribiose, manobiose, melibiose, nigerose, rutinose, xylobiose, lactulose and combinations thereof.

[0112] Non-limiting examples of trioses may include glyceraldehyde, dihydroxyacetone, and combinations thereof.

[0113] Non-limiting examples of tetroses may include erythrose, threosis, erythrulose, and combinations thereof.

[0114] Non-limiting examples of pentoses may include arabinose, lyxose, ribose, xylose, ribulose, xylulose and combinations thereof.

[0115] Non-limiting examples of hexoses may include allose, altrose, galactose, glucose, gulose, idose, mannose, talose, fructose, psicose, sorbose, tagatose and combinations thereof.

[0116] Non-limiting examples of heptoses may include manoeptulose, sedoeptulose, and combinations thereof.

[0117] Non-limiting examples of octoses may include octolose, 2-keto-3-deoxy-mannanoctonate, and combinations thereof. A non-limiting example of a nonose may include sialose.

[0118] The oral treatment composition may comprise from about 0.01% to about 50%, from about 0.1% to about 50%, from about 1% to about 40%, from about 2% to about 25%, from about 5% to about 15% or from about 5% to about 10% of a polyol by weight of the oral treatment composition. Water

[0119] The composition for oral treatment may comprise from about 0.01% to about 50% by weight of Petition 870210111416, dated 01 / 12 / 2021, page 40 / 104 35 / 83 water, of the composition for oral treatment. The composition for oral treatment may comprise from about 0.01% to about 30%, from about 0.1% to about 25%, from about 0.5% to about 15% or from about 1% to about 15% of water by weight of the composition. The water may be added to the formulation directly and / or may enter the composition from the inclusion of other ingredients. Preferably, the water is USP water. Alternatively, the oral treatment composition may comprise less than about 5%, less than about 1%, less than about 0.5%, or less than about 0.01% of water by weight of the total composition. The oral treatment composition may not comprise added water beyond the minimum amount of water in commercial products incorporated into the oral treatment composition or water incorporated under ambient conditions. Abrasive

[0120] The oral treatment composition may comprise from about 0.5% to about 75% of an abrasive, by weight, of the oral treatment composition. The oral treatment composition may comprise from about 5% to about 60%, from about 10% to about 50%, or from about 15% to about 55%, or combinations thereof, of an abrasive by weight of the composition. The abrasive may be a calcium-containing abrasive, a silica-based abrasive, a carbonate abrasive, a phosphate abrasive, an alumina abrasive, other suitable abrasives, and / or combinations thereof. Some abrasives may fall into several descriptive categories, such as calcium carbonate, which is both a calcium-containing abrasive and a carbonate abrasive. Petition 870210111416, dated 01 / 12 / 2021, page 41 / 104 36 / 83

[0121] Calcium-containing abrasives may comprise calcium carbonate, dicalcium phosphate, tricalcium phosphate, calcium orthophosphate, calcium metaphosphate, calcium polyphosphate, calcium hydroxyapatite and combinations thereof.

[0122] Calcium-containing abrasives may comprise calcium carbonate. Calcium-containing abrasives may be selected from the group consisting of finely ground natural chalk, ground calcium carbonate, precipitated calcium carbonate, and combinations thereof.

[0123] The carbonate abrasive may comprise sodium carbonate, sodium bicarbonate, calcium carbonate, strontium carbonate and / or combinations thereof.

[0124] Phosphate abrasive may comprise calcium phosphate, sodium hexametaphosphate, dicalcium phosphate, tricalcium phosphate, calcium orthophosphate, calcium metaphosphate, calcium polyphosphate, a polyphosphate, a pyrophosphate, and / or combinations thereof.

[0125] Silica-based abrasive may comprise fused silica, pyrolyzed silica, precipitated silica, hydrated silica, and / or combinations thereof.

[0126] Alumina abrasive may comprise polycrystalline alumina, calcined alumina, fused alumina, levigated alumina, hydrated alumina, and / or combinations thereof.

[0127] Other suitable abrasives include diatomaceous earth, barium sulfate, wollastonite, perlite, polymethyl methacrylate particles, tospearl, and combinations thereof. Petition 870210111416, dated 01 / 12 / 2021, page 42 / 104 37 / 83

[0128] The abrasive can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Source of fluoride ions

[0129] Oral treatment compositions may include an effective amount of an anti-caries agent. The oral treatment composition may comprise a source of fluoride ion.

[0130] The fluoride ion source may be present in a sufficient amount to yield an adequate fluoride ion concentration in the composition in accordance with local laws and regulations, for example the FDA anticaries monograph. The oral treatment composition may comprise from about 0.0025% to about 20%, from about 0.0025% to about 10%, from about 0.01% to about 5%, or from about 0.0025% to about 2%, by weight of the oral treatment composition, of the fluoride ion source.

[0131] The fluoride ion source may be in an amount suitable to obtain a theoretical fluoride concentration of about 200 ppm to about 10000 ppm, about 200 ppm to about 2000 ppm, about 800 ppm to about 1500 ppm, or about 1100 ppm to about 1400 ppm as standardized for a unit dose oral treatment composition by the addition of water.

[0132] The fluoride ion source may comprise examples of suitable materials that provide fluoride ions and are disclosed in U.S. Patents Nos. 3,535,421 and 3,678,154. The fluoride ion source may comprise stannous fluoride, sodium fluoride, potassium fluoride, amine fluoride, Petition 870210111416, dated 01 / 12 / 2021, page 43 / 104 38 / 83 sodium monofluorophosphate, zinc fluoride and / or combinations thereof.

[0133] The fluoride ion source and the metal ion source can be the same compound, such as stannous fluoride, which can generate tin ions and fluoride ions. Additionally, the fluoride ion source and the tin ion source can be separate compounds, such as when the metal ion source is stannous chloride and the fluoride ion source is sodium monofluorophosphate or sodium fluoride.

[0134] The fluoride ion source can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Source of metal ions

[0135] The oral treatment composition may comprise a source of metal ions. Suitable sources of metal ions include stannous ion sources, zinc ion sources, copper ion sources, silver ion sources, magnesium ion sources, iron ion sources, sodium ion sources, and manganese (Mn) ion sources, and / or combinations thereof. The metal ion source may be a soluble or moderately soluble compound of stannous, zinc, or copper with inorganic or organic counterions. Some examples include fluoride, chloride, chlorofluoride, acetate, hexafluorozirconate, sulfate, tartrate, gluconate, citrate, malate, glycinate, pyrophosphate, metaphosphate, oxalate, phosphate, carbonate salts, and oxides of stannous, zinc, and copper.

[0136] Stanous, zinc, and copper ions are derived from the metal ion source(s) and can be Petition 870210111416, dated 01 / 12 / 2021, page 44 / 104 39 / 83 found in the composition for multiphase oral treatment in an amount effective to provide an oral treatment benefit or other benefits. Stannous, zinc, and copper ions have been found to help reduce gingivitis, plaque, and sensitivity and provide breath-improving benefits. An effective amount is defined as at least about 500 ppm to about 20,000 ppm of metal ions in the total composition, preferably about 2,000 ppm to about 15,000 ppm. More preferably, metal ions are present in an amount of about 3,000 ppm to about 13,000 ppm, and even more preferably about 5,000 ppm to about 10,000 ppm. This is the total amount of metal ions (stannous, zinc, copper, and mixtures thereof) present in the compositions for application to the dental surface.

[0137] Other sources of metal ions may include minerals and / or compounds containing calcium, which may lead to remineralization, such as, for example, sodium iodide, potassium iodide, calcium chloride, calcium lactate, calcium phosphate, hydroxyapatite, fluoroapatite, amorphous calcium phosphate, crystalline calcium phosphate, sodium bicarbonate, sodium carbonate, calcium carbonate, oxalic acid, dipotassium oxalate, monosodium monopotassium oxalate, casein phosphopeptides and / or hydroxyapatite coated with casein phosphopeptide.

[0138] The source of metal ions may comprise a metal salt suitable for generating metal ions in the oral cavity. Suitable metal salts include silver (Ag), magnesium (Mg), iron (Fe), sodium (Na) and salts. Petition 870210111416, dated 01 / 12 / 2021, page 45 / 104 40 / 83 manganese (Mn), or combinations thereof. Preferred salts include, without limitation, gluconates, chlorates, citrates, chlorides, fluorides, and nitrates, or combinations thereof.

[0139] The oral treatment composition may comprise at least about 0.005%, from about 0.005% to about 10%, from about 0.01% to about 5%, from about 0.01% to about 2%, or from about 0.1% to about 1%, of a metal ion source by weight of the oral treatment composition. The metal ion source may be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Tin ion source

[0140] Tin ions, such as stannous ions, are used in oral treatment compositions to provide benefits such as enamel treatment and cavity protection. Suitable sources of tin ions include stannous chloride, stannous fluoride, stannous bromide, stannous iodide, stannous acetate, stannous gluconate, stannous oxalate, stannous sulfate, stannous lactate, stannous tartrate, stannous carbonate, stannic chloride, stannic fluoride, stannic iodide, stannous citrate, stannic nitrate, stannous peptides, stannous proteins, and stannous phosphate, and combinations thereof. Preferably, the ion source is stannous fluoride, stannous chloride, and / or combinations thereof.

[0141] The oral treatment compositions of the present invention may comprise a source of tin ions in an amount in the range of about 0.01% to about Petition 870210111416, dated 01 / 12 / 2021, page 46 / 104 41 / 83 of 5%, from about 0.05% to about 4%, from about 0.01% to about 10%, or from 0.075% to about 3%. The tin ion source may be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Source of zinc ions

[0142] The oral treatment composition may comprise from about 0.01% to about 5%, from about 0.2% to about 2%, or from about 0.01% to about 10% of a zinc ion source by weight of the oral treatment composition. The zinc ion source may be selected from the group consisting of zinc citrate, zinc chloride, zinc sulfate, zinc gluconate, zinc lactate, zinc phosphate, zinc arginine, zinc fluoride, zinc iodide, zinc carbonate, and combinations thereof. More preferably, the zinc ion source is selected from zinc citrate, zinc gluconate, zinc lactate, and combinations thereof. Insoluble or moderately soluble zinc compounds, such as zinc oxide or zinc carbonate, may be used as the zinc ion source. The zinc ion sources may be soluble zinc sources, such as zinc chloride or zinc sulfate.Additionally, zinc ion sources can be those where zinc is already combined with a suitable chelating agent in the form of a salt or other complex, such as zinc citrate, zinc gluconate, zinc lactate, and zinc glycinate. Other examples of zinc ion sources are zinc citrate, zinc gluconate, zinc lactate, and mixtures thereof. Petition 870210111416, dated 01 / 12 / 2021, page 47 / 104 42 / 83

[0143] When insoluble and soluble zinc compounds are both present in the zinc ion source, the soluble zinc compound may be present in at least about 50% by weight of the total zinc ion source. The oral treatment compositions of the present invention may optionally also include other antibacterial agents, preferably present in an amount of about 0.035% or more, from about 0.05% to about 2%, from about 0.1% to about 1% by weight of the oral treatment composition. Examples of such other antimicrobial agents may include antibacterial agents such as, for example, halogenated diphenyl ethers, phenolic compounds including phenol and its homologues, mono- and polyalkyl and halophenolic aromatics, resorcinol and its derivatives, xylitol, bisphenolic compounds and halogenated salicylanilides, benzoic esters and halogenated carbanilides.Other useful antibacterial agents are enzymes, including endoglucosidase, papain, dextranase, mutanase, and combinations thereof. Another example of an antibacterial agent could be triclosan (5-chloro-2-(2,4-dichlorophenoxy)phenol).

[0144] The zinc ion source can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Copper ion source

[0145] The oral treatment composition may comprise from about 0.01% to about 5%, from about 0.2% to about 2%, or from about 0.01% to about 10%, by weight of the oral treatment composition, of a source of Petition 870210111416, dated 01 / 12 / 2021, page 48 / 104 43 / 83 Copper ion. The copper ion source may be selected from the group consisting of copper gluconate, copper citrate, copper fluoride, copper iodide, copper bromide, copper peptides, copper sulfate, copper arginine, copper carbonate, and combinations thereof. Copper salts may be in any possible oxidation state, including, for example, copper(I) or copper(II) salts. The copper ion source may be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Calcium ion source

[0146] The oral treatment composition may comprise a calcium ion source. The calcium ion source may comprise a calcium salt, such as calcium chloride, and / or a calcium-containing abrasive, as described herein.

[0147] The calcium compound may comprise any suitable soluble calcium salt, such as, for example, calcium chloride, calcium carbonate, calcium bicarbonate, calcium hydroxide, calcium lactate, calcium citrate, calcium phosphate and combinations thereof.

[0148] The oral treatment composition may comprise from about 0.01% to about 10%, from about 1% to about 50%, from about 10% to about 50% or from about 1% to about 30%, by weight, of a calcium ion source of the oral treatment composition. Surfactants

[0149] The oral treatment composition may comprise one or more surfactants. The fibrous composition Petition 870210111416, dated 01 / 12 / 2021, page 49 / 104 44 / 83 may comprise one or more surfactants. The non-fibrous composition may comprise one or more surfactants. One or more surfactants may be selected from anionic, non-ionic, amphoteric, zwitterionic, cationic surfactants or combinations thereof.

[0150] The oral treatment composition may include one or more surfactants in a content of about 0.01% to about 20%, about 1% to about 15%, about 0.1% to about 15%, about 5% to about 15%, or greater than about 5% by weight of the composition.

[0151] Suitable anionic surfactants include, for example, water-soluble alkyl sulfate salts having 8 to 20 carbon atoms in the alkyl radical and water-soluble sulfonated monoglyceride salts of fatty acids having 8 to 20 carbon atoms. Sodium lauryl sulfate (SLS) and sodium sulfonates of coconut monoglycerides are examples of anionic surfactants of this type. Other suitable anionic surfactants include sarcosinates, such as sodium lauroyl sarcosinate, taurates, sodium lauryl sulfoacetate, sodium lauroyl isethionate, sodium laureth carboxylate, and sodium dodecylbenzene sulfonate. Combinations of anionic surfactants may also be employed.

[0152] Another suitable class of anionic surfactants are alkyl phosphates. Surface-active organophosphate agents can have a strong affinity for the enamel surface and have sufficient surface-binding propensity to desorb pellicle proteins and remain attached to enamel surfaces. Suitable examples of compounds of Petition 870210111416, dated 01 / 12 / 2021, pages 50 / 104 45 / 83 Organophosphates include mono-, di-, and triesters represented by the general structure below, wherein Z1, Z2, or Z3 may be identical or different, with at least one being an organic moiety. Z1, Z2, or Z3 may be selected from a linear or branched alkyl or alkenyl group of 1 to 22 carbon atoms, optionally substituted by one or more phosphate groups; an alkoxylated alkyl or alkenyl group, (poly)saccharide, polyol, or polyether. THE P O—z3

[0153] Some other agents include alkyl or alkenyl phosphate esters represented by the following structure: THE Ri---(OCnH2n)a(OCmH2m)b---O---P---O---Z2 OI Z3 with R1 representing a linear or branched alkyl or alkenyl group of 6 to 22 carbon atoms, optionally substituted by one or more phosphate groups; neither are, individually and separately, from 2 to 4, and aeb, individually and separately, are from 0 to 20; Z and Z may be Petition 870210111416, dated 01 / 12 / 2021, p. 51 / 104 46 / 83 identical or different, each representing hydrogen, alkali metal, ammonium, protonated alkylamine or protonated functional alkylamine, such as an alkanolamine, or an R—(OCH2)(OCH)- group. Examples of suitable agents include alkyl phosphates and alkyl(poly)alkoxy phosphates such as lauryl phosphate; PPGS cetearet-10 phosphate; laureth-1 phosphate; laureth-3 phosphate; laureth-9 phosphate; trilauret-4 phosphate; PEG 9 C12-18 phosphate; and dilauret-10 sodium phosphate. The alkyl phosphate may be polymeric. Examples of polymeric alkyl phosphates include those containing repeating alkoxy groups as the polymeric moiety, in particular 3 or more ethoxy, propoxy, isopropoxy or butoxy groups.

[0154] Other suitable surfactants are sarcosinates, isethionates and taurates, especially their alkali metal or ammonium salts. Examples include: lauroyl sarcosinate, myristoyl sarcosinate, palmitoyl sarcosinate, stearoyl sarcosinate, oleoyl sarcosinate or combinations thereof.

[0155] Zwitterionic or amphoteric surfactants useful in the present invention include derivatives of aliphatic quaternary ammonium compounds, phosphonium and sulfonium, in which the aliphatic radicals may be linear or branched chain and one of the aliphatic substituents contains from 8 to 18 carbon atoms and one contains a water-solubilizing anionic group, for example, carboxy, sulfonate, sulfate, phosphate or phosphonate. Suitable betaine-based surfactants are disclosed in US Patent No. 5,180,577. Typical dimethyl alkyl betaines include decyl betaine or 2-(N-decyl-N,N-dimethyl acetate). Petition 870210111416, dated 01 / 12 / 2021, page 52 / 104 47 / 83 ammonium), coco-betaine or 2-(N-coco-N,N-dimethyl ammonium acetate), myristyl betaine, palmityl betaine, lauryl betaine, cetyl betaine, cetyl betaine, stearyl betaine, etc. Amidobetaines can be exemplified by cocoamido ethyl betaine, cocamido propyl betaine (CAPB), and lauramid propyl betaine.

[0156] Useful cationic surfactants in the present invention include, for example, derivatives of quaternary ammonium compounds having a long alkyl chain containing from 8 to 18 carbon atoms such as lauryl trimethyl ammonium chloride; cetylpyridinium chloride, cetyl-trimethyl ammonium bromide; cetylpyridinium fluoride or combinations thereof.

[0157] Nonionic surfactants that can be used in the compositions of the present invention include, for example, compounds produced by the condensation of alkylene oxide groups (of a hydrophilic nature) with a hydrophobic organic compound, which may be of an aliphatic or alkyl aromatic nature. Examples of suitable nonionic surfactants may include Pluronics® which are poloxamers, alkyl phenol polyethylene oxide condensates, products derived from the condensation of ethylene oxide with the reaction product of propylene oxide and ethylenediamine, aliphatic alcohol ethylene oxide condensates, long-chain tertiary amine oxides, long-chain tertiary phosphine oxides, long-chain dialkyl sulfoxides, and combinations of these materials.

[0158] One or more surfactants may also include one or more natural surfactants. Natural surfactants may include surfactants that are derived from Petition 870210111416, dated 01 / 12 / 2021, pp. 53 / 104 48 / 83 natural products and / or surfactants that are minimally processed or unprocessed. Surfactants may include hydrogenated, non-hydrogenated, or partially hydrogenated vegetable oils, olus oil, passionflower oil, candelilla wax, coco-caprylate, caprate, dicaprylyl ether, lauryl alcohol, myristyl myristate, dicaprylyl ether, caprylic acid, caprylic ester, octyl decanoate, octyl octanoate, undecane, tridecane, decyl oleate, oleic acid decyl ester, cetyl palmitate, stearic acid, palmitic acid, glyceryl stearate, hydrogenated, non-hydrogenated, or partially hydrogenated vegetable glycerides, polyglyceryl-2 dipolyhydroxy stearate, cetearyl alcohol, sucrose polystearate, glycerin, octadodecanol, hydrolyzed, partially hydrolyzed, or non-hydrolyzed vegetable protein, wheat protein hydrolysate. hydrolyzed, partially hydrolyzed, or non-hydrolyzed polyglyceryl-3 diisostearate,Glyceryl oleate, myristyl alcohol, cetyl alcohol, sodium cetearyl sulfate, cetearyl alcohol, glyceryl laurate, capric triglyceride, coco-glycerides, lecithin, dicaprylyl ether, xanthan gum, sodium coco-sulfate, ammonium lauryl sulfate, sodium cocoyl sulfate, sodium cocoyl glutamate, polyalkyl glycosides, such as decyl glycoside, cetearyl glycoside, cetyl stearyl polyglycoside, coco-glucoside and lauryl glucoside and / or combinations thereof. Natural surfactants may include any of the Natrue ingredients marketed by BASF, such as, for example, CegeSoft®, Cetiol®, Cutina®, Dehymuls®, Emulgade®, Emulgin®, Eutanol®, Gluadin®, Petition 870210111416, dated 01 / 12 / 2021, pp. 54 / 104 49 / 83 Lameform®, LameSoft®, Lanette®, Monomuls®, Myritol®, Plantacare®, Plantaquat®, Platasil®, Rheocare®, Sulfopon®, Texapon®, and / or combinations thereof.

[0159] The surfactant may be formed within the fibrous composition, added to the surface of the fibrous composition, and / or included in the non-fibrous composition. The surfactant formed within the fibrous composition may be at a level of about 10% to about 50%, about 20% to about 40%, about 25% to about 40%, or about 30% to about 40%, by weight of the fibrous composition.

[0160] The oral treatment composition may comprise one or more surfactants. The oral treatment composition may comprise an anionic surfactant, a cationic surfactant, a nonionic surfactant and / or a zwitterionic surfactant.

[0161] The oral treatment composition may comprise from about 0.1% to about 10%, from about 0.1% to about 8%, from about 5% to about 8%, from about 4% to about 9% or from about 3% to about 10% of an anionic surfactant, cationic surfactant and / or nonionic surfactant by weight of the composition.

[0162] The oral treatment composition may comprise from about 0.01% to about 20%, from about 0.01% to about 10%, from about 0.1% to about 1%, from about 0.01% to about 1%, from about 0.01% to about 0.5%, or from about 0.1% to about 0.2% of a zwitterionic surfactant by weight of the composition. Petition 870210111416, dated 01 / 12 / 2021, pages 55 / 104 50 / 83 PEG

[0163] The oral treatment composition may comprise poly(ethylene glycol) (PEG) with various percentages by weight of the composition, as well as various ranges of average molecular weights. The compositions may have from about 0.1% to about 40%, from about 1% to about 35%, from about 5% to about 30%, from about 15% to about 25%, from about 1% to about 40%, from about 10% to about 30%, from about 15% to about 20%, from about 0.1% to about 30%, or from about 15% to about 30% of PEG by weight of the composition. PEG can have an average molecular weight range of about 100 Daltons to about 1600 Daltons, about 200 to about 1000, about 400 to about 800, about 500 to about 700 Daltons, or combinations thereof. PEG is a water-soluble linear polymer formed by the addition reaction of ethylene oxide to an equivalent of ethylene glycol with the following general formula: H-(OCH2CH2)n-OH.One supplier of PEG is the Dow Chemical Company, operating under the trade name CARBOWAX™.

[0164] PEG can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. The PEG included in the non-fibrous composition can be at a level of about 10% to about 50%, about 15% to about 40%, about 5% to about 35%, or about 15% to about 30%, by weight of the non-fibrous composition. When used as a solvent for the non-fibrous composition, PEG can be anhydrous to avoid reactivity between the components dispersed or dissolved in the PEG. Petition 870210111416, dated 01 / 12 / 2021, pages 56 / 104 51 / 83 Polyphosphates

[0165] A composition for oral treatment may comprise a polyphosphate source. A polyphosphate source may comprise one or more polyphosphate molecules. Polyphosphates are a class of materials obtained by the dehydration and condensation of orthophosphate to produce linear and cyclic polyphosphates of varying chain lengths. Thus, polyphosphate molecules are generally identified with an average number (n) of polyphosphate molecules, as described below. It is generally understood that a polyphosphate consists of two or more phosphate molecules arranged primarily in a linear configuration, although some cyclic derivatives may be present.

[0166] Preferred polyphosphates are those having an average of two or more phosphate groups such that surface adsorption at effective concentrations produces sufficient unbound phosphate functions, which accentuates the anionic charge of the surface as well as the hydrophilic character of the surfaces. Preferred in this invention are linear polyphosphates having the formula: XO(XPO3)nX, where X is sodium, potassium, ammonium or any other alkali metal cations and has an average of about 2 to about 21. The polyphosphate source may also include alkaline earth metal polyphosphate salts and specifically calcium polyphosphate salts such as calcium pyrophosphate, due to the ability to separate calcium ions from other reactive components, such as fluoride ion sources. Petition 870210111416, dated 01 / 12 / 2021, page 57 / 104 52 / 83

[0167] Some examples of suitable polyphosphate molecules include, for example, pyrophosphate (n=2), tripolyphosphate (n=3), tetrapolyphosphate (n=4), sodaphos polyphosphate (n=6), hexaphos polyphosphate (n=13), benephos polyphosphate (n=14), hexametaphosphate (n=21), which is also known as Glass H. Polyphosphates may include those polyphosphate compounds produced by FMC Corporation, ICL Performance Products and / or Astaris.

[0168] The oral treatment composition may comprise from about 0.01% to about 15%, from about 0.1% to about 10%, from about 0.5% to about 5%, from about 1% to about 20%, or from about 10% or less, by weight of the oral treatment composition of the polyphosphate source. Extension auxiliary means

[0169] The oral treatment composition may comprise an extensional auxiliary medium. Non-limiting examples of extensional auxiliaries may include polymers, other extensional auxiliaries, and combinations thereof.

[0170] The extensional auxiliary media may have a weight-average molecular weight of at least about 500,000 Da. The weight-average molecular weight of the extensional auxiliary media may be from about 500,000 to about 25,000,000, from about 800,000 to about 22,000,000, from about 1,000,000 to about 20,000,000, or from about 2,000,000 to about 15,000,000. High molecular weight extensional auxiliary media are preferred in some embodiments of the invention due to their ability to Petition 870210111416, dated 01 / 12 / 2021, pp. 58 / 104 53 / 83 increase the viscosity of the extensional molten material and reduce fracture of the molten material.

[0171] The extensional auxiliary medium, when used in blow spinning, can be added to the composition of the present invention in an amount effective to visibly reduce molten material fracture and filament capillary breakage during the spinning process so that substantially continuous filaments having a relatively consistent diameter can be melt spun. Regardless of the process employed to produce the filaments, the extensional auxiliary media, when used, may be present from about 0.001% to about 10% by weight, based on a dry filament, from about 0.005% to about 5% by weight, based on a dry filament, from about 0.01% to about 1% by weight, based on a dry filament, or from about 0.05% to about 0.5% by weight, based on a dry filament.

[0172] Non-limiting examples of polymers that may optionally be used as extensional auxiliary media may include alginates, carrageenans, pectin, chitin, guar gum, xanthan gum, agar, gum arabic, karaya gum, tragacanth gum, locust bean gum, alkyl cellulose, hydroxyalkyl cellulose, carboxyalkylcellulose and mixtures thereof.

[0173] Non-limiting examples of other extensional auxiliaries may include carboxyl-modified polyacrylamide, acrylic polyacid, polymethacrylic acid, polyvinyl alcohol, polyvinyl acetate, polyvinylpyrrolidone, polyethylene vinyl acetate, polyethyleneimine, polyamides, polyalkylene oxides Petition 870210111416, dated 01 / 12 / 2021, pp. 59 / 104 54 / 83 including polyethylene oxide, polypropylene oxide, polyethylenepropylene oxide, and mixtures thereof. Aesthetic agents

[0174] The oral treatment composition may optionally comprise one or more aesthetic agents. The one or more aesthetic agents may be selected from the group consisting of flavorings, colorings, sensory elements, sweeteners, salivation agents and combinations thereof. All aesthetic agents may be present from about 0.001% to about 60% by weight of the oral treatment composition, from about 0.005% to about 50% by weight of the oral treatment composition, from about 0.05% to about 40% by weight of the oral treatment composition, or from about 0.1% to about 35% by weight of the oral treatment composition.

[0175] Aesthetic agents can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Flavorings

[0176] The oral treatment composition may optionally include one or more flavorings. Non-limiting examples of flavorings that may be used in the present invention may include natural flavoring agents, artificial flavoring agents, artificial extracts, natural extracts, and combinations thereof. Non-limiting examples of flavorings may include vanilla, honey, lemon, honey with lemon, cherry vanilla, peach, honey ginger, chamomile, cherry, cherry cream, mint, vanilla mint, dark berry, black berry, raspberry, peppermint, spearmint, honey peach, acai berry, Petition 870210111416, dated 01 / 12 / 2021, pages 60 / 104 55 / 83 cranberry, cranberry honey, tropical fruits, dragon fruit, goji berries, red mint, pomegranate, blackcurrant, strawberry, lemon, lime, ginger, peach, orange, orange cream, creamy orange popsicle, apricot, anethole, ginger, jackfruit, star fruit, blueberry, fruit punch, lemongrass, lemongrass chamomile, lavender, banana, banana and strawberry, grape, blue raspberry, lime, coffee, espresso, cappuccino, honey, mint and wintergreen, chewing gum, honey and lemon pie, sour lemon, green apple, boysenberry, rhubarb, rhubarb and strawberry, persimmon, green tea, black tea, red tea, white tea, lime and honey, lime and cherry, apple, tangerine, grapefruit, kiwi, pear, vanillin, ethyl vanillin, maltol, ethyl maltol, pumpkin, carrot cake, raspberry and white chocolate, chocolate, white chocolate, chocolate milk, dark chocolate, chocolate marshmallow, apple pie, cinnamon, hazelnut, almond, cream, crème brûlée, caramel, caramel ring, butter, butterscotch, caramel toffee.aloe vera, whiskey, rum, cocoa, licorice, pineapple, guava, melon, watermelon, elderberry, mouth cooler, raspberries and cream, mango and peach, tropical, berry refreshment, lemon tea, nectar, spicy nectar, tropical mango, apple butter, peanut butter, tangerine, lime and tangerine, marshmallow, cotton candy, apple cider, chocolate and orange, adipic acid, citral, denatonium benzoate, ethyl acetate, ethyl lactate, ethyl maltol, ethyl cellulose, fumaric acid, leucine, malic acid, menthol, methionine, monosodium glutamate, sodium acetate, sodium lactate, tartaric acid, thymol and combinations thereof. Petition 870210111416, dated 01 / 12 / 2021, pp. 61 / 104 56 / 83

[0177] Flavorings may be protected in an encapsulated form or as a flavoring crystal. The encapsulated flavoring may have a delayed or controlled release when the encapsulated flavoring reaches the oral cavity. The encapsulated form may comprise a carcass and a core. The flavoring may be in the core of the encapsulated form. The flavoring may be encapsulated by any suitable means, such as spray drying or extrusion. Encapsulated flavorings may be added to the surface of the fibrous composition, formed within the fibrous composition, or included in the non-fibrous composition.

[0178] Flavorings may be present from about 0.05% to about 25% by weight of the oral treatment composition, from about 0.01% to about 15% by weight of the oral treatment composition, from about 0.2% to about 10% by weight of the oral treatment composition, or from about 0.1% to about 5% by weight of the oral treatment composition.

[0179] Flavorings may be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Colorants

[0180] The oral treatment composition may optionally include one or more dyes. The dyes may provide a visual signal when the oral treatment composition is exposed to the intended conditions of use. Non-limiting examples of dyes that may be used in the present invention include FD&C Blue No. 1, FD&C Blue No. 2, D&C Blue No. 4, D&C Blue No. 9, FD&C Green No. 3, green Petition 870210111416, dated 01 / 12 / 2021, pages 62 / 104 57 / 83 D&C No. 5, green; D&C No. 6, green; D&C No. 8, orange; D&C No. 4, orange; D&C No. 5, orange; D&C No. 10, orange; D&C No. 11, red; FD&C No. 3, red; FD&C No. 4, red; D&C No. 6, red; D&C No. 7, red; D&C No. 17, red; D&C No. 21, red; D&C No. 22, red; D&C No. 27, red; D&C No. 28, red; D&C No. 30, red; D&C No. 31, red; D&C No. 33, red; D&C No. 34, red; D&C No. 36, red; D&C No. 39, red; FD&C No. 40, violet; D&C No. 2, yellow; FD&C No. 5, yellow; FD&C No. 6, D&C Yellow No. 7, D&C Yellow No. 7, D&C Yellow No. 8, D&C Yellow No. 10, D&C Yellow No. 11, and combinations thereof. The dyes may be present from about 0.05% to about 2% by weight of the oral treatment composition, from about 0.01% to about 2% by weight of the oral treatment composition, or from about 0.02% to about 1.5% by weight of the oral treatment composition.

[0181] Dyes can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Sensory elements

[0182] The oral treatment composition may optionally include one or more sensory elements. Some non-limiting examples of sensory elements may include cooling sensory elements, warming sensory elements, tingling sensory elements, and combinations thereof. Sensory elements are useful for delivering signals to the user.

[0183] Non-limiting examples of cooling sensor elements may include WS-23 (2-Isopropyl-N,2,3-trimethylbutyramide), WS-3 (N-ethyl-pPenitence 870210111416, dated 01 / 12 / 2021, page 63 / 104 58 / 83 menthane-3-carboxamide), WS-30 (1-glyceryl-p-menthane-3-carboxylate), WS-4 (ethylene glycol-p-methane-3-carboxylate), WS-14 (N-butyl-p-menthane-3-carboxamide), WS-12 (N-(4-ethoxyphenyl)-p-menthane-3-carboxamide), WS-5 (ethyl-3-(p-menthane-3-carboxamide) acetate, Menthone glycerol ketal (sold as Frescolat® MGA by Haarmann & Reimer), (-)-mentyl lactate (sold as Frescolat® ML by Haarmann & Reimer), (-)-mentoxypropane-1,2-diol (sold as Refrigerant Agent 10 by Takasago International), 3-(l-mentoxy)propane-1,2-diol, 3-(l-mentoxy)-2-methylpropane-1,2-diol, (-) Isopulegol is commercially available under the name Coolact P® by Takasago International., cis & trans p-Menthane-3,8-diois(PMD38) Takasago International, Questice® (menthyl pyrrolidone carboxylate), (1R,3R,4S)-3-menthyl-3,6-dioxaeptanoate Firmenich, (1R,2S,5R)-3-3-methoxyacetate Menthyl Firmenich, (1R,2S,5R)-3-menthyl 3,6,9-trioxadecanoate Firmenich, (1R,2S,5R)-menthyl 11-hydroxy-3,6,9trioxaundecanoate-Firmenich, (1R,2S,5R)-3-menthyl (2hydroxy ethoxy)acetate - Firmenich, Cubebol - Firmenich, Icilin also known as AG-3-5, chemical name 1-[2hydroxy phenyl]-4-[2-nitrophenyl-]-1,2,3,6-tetrahydropyrimidine-2-one), 4-methyl-3-(1-pyrrolidinyl)-2[5H]furanone, Frescolat ML - menthyl lactate, Frescolat MGA. - Menthol glycerin acetal, peppermint oil, Givaudan 180, L-Monomentyl succinate, L-monomentyl glutarate, 3-L-mentoxypropane-1,2-diol (Coolact 10), 2-L-mentoxyethanol (Cooltact 5), TK10 Coolact (3-L-mentoxypropane-1,2-diol), Evercool 180 (NP-benzeneacetonitrile-menthane carboxamide), and combinations thereof. The elements Petition 870210111416, dated 01 / 12 / 2021, pages 64 / 104 59 / 83 Cooling sensory properties may be present from about 0.005% to about 10% by weight of the oral treatment composition, from about 0.05% to about 7% by weight of the oral treatment composition, or from about 0.01% to about 5% by weight of the oral treatment composition.

[0184] Non-limiting examples of warming sensory elements may include TK 1000, TK 1 MM, Heatenol - Sensient Flavorings, Optaheat Symrise Flavorings, Cinnamon, Polyethylene glycol, Capsicum, Capsaicin, Curry, FSI Flavorings, Isobutavane, Ethanol, Glycerin, Nonivamide 60162807, Hotact VEE, Hotact 1MM, piperine, optaheat 295 832, optaheat 204 656, optaheat 200 349 and combinations thereof. The warming sensory elements may be present from about 0.005% to about 60% by weight based on a dry filament, from about 0.05% to about 50% by weight based on a dry filament, or from about 0.01% to about 40% by weight based on a dry filament. The warming sensory elements may be present from about 0.005% to about 10% by weight of the oral treatment composition, from about 0.05% to about 7% by weight of the oral treatment composition, or from about 0.01% to about 5% by weight of the oral treatment composition.

[0185] Non-limiting examples of tingling sensory elements may include Sichuan pepper, alpha hydroxy sanshool, citric acid, jambu extracts, spilanthol, and combinations thereof. Tingling sensory elements may be present from about 0.005% to about 10% by weight based on a dry filament or in Petition 870210111416, dated 01 / 12 / 2021, pages 65 / 104 60 / 83 composition for oral treatment, from about 0.01% to about 7% by weight based on a dry filament or in the composition for oral treatment, or from about 0.015% to about 6% by weight based on a dry filament or in the composition for oral treatment.

[0186] Sensory elements can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Sweeteners

[0187] The oral treatment composition may optionally include one or more sweeteners. The sweeteners may be natural or synthetic. Non-limiting examples of sweeteners may include nutritive sweeteners, sugar alcohols, synthetic sweeteners, high-intensity natural sweeteners, and combinations thereof. All sweeteners may be present from about 0.05% to about 60% by weight of the oral treatment composition, from about 0.1% to about 50% by weight of the oral treatment composition, or from about 1% to about 10% by weight of the oral treatment composition.

[0188] Non-limiting examples of nutritive sweeteners may include sucrose, dextrose, glucose, fructose, lactose, tagatose, maltose, trehalose, and combinations thereof. Nutritive sweeteners may be present from about 0.1% to about 60% by weight of the oral treatment composition, from about 1% to about 50% by weight of the oral treatment composition, or from about 0.1% to about 10% by weight of the oral treatment composition. Petition 870210111416, dated 01 / 12 / 2021, pages 66 / 104 61 / 83

[0189] Non-limiting examples of sugar alcohols may include xylitol, sorbitol, mannitol, maltitol, lactitol, isomalt, erythritol, and combinations thereof. Sugar alcohols may be present from about 0.1% to about 60% by weight of the oral treatment composition, from about 0.11% to about 50% by weight of the oral treatment composition, or from about 0.1% to about 10% by weight of the oral treatment composition.

[0190] Non-limiting examples of synthetic sweeteners may include aspartame, acesulfame potassium, alitame, sodium saccharin, sucralose, neotame, cyclamate, and combinations thereof. Synthetic sweeteners may be present from about 0.05% to about 10% by weight of the oral treatment composition, from about 0.1% to about 5% by weight of the oral treatment composition, or from about 0.25% to about 4% by weight of the oral treatment composition.

[0191] Non-limiting examples of high-intensity natural sweeteners may include neohesperidin dihydrochalcone, stevioside, rebaudioside A, rebaudioside C, dulcoside, monoammonium glycyrrhizinate, thaumatin, and combinations thereof. High-intensity natural sweeteners may be present from about 0.05% to about 10% by weight of the oral treatment composition, from about 0.1% to about 5% by weight of the oral treatment composition, or from about 0.25% to about 4% by weight of the oral treatment composition.

[0192] Sweeteners can be formed into the nonwoven fabric, added to the surface of the nonwoven fabric, or included in the nonfibrous composition. Petition 870210111416, dated 01 / 12 / 2021, pages 67 / 104 62 / 83 Saliva-producing agents

[0193] The oral treatment composition may include one or more salivating agents. Non-limiting examples of salivating agents include formula (I): R1 O R3 (I) where R1 represents C1-C2 n-alkyl; R2 is 2-methyl-1-propyl and R3 is hydrogen or R2 and R3 taken together in a portion (designated by dashed lines) having the formula (CH2)n- where n is 4 or 5 and combinations thereof.

[0194] The salivation agent may comprise a material wherein R2 is 2-methyl-1-propyl and R3 is hydrogen or the salivation agent may comprise a material wherein R1 is C1 n-alkyl, R2 is 2-methyl-1-propyl and R3 is hydrogen. The salivation agent may comprise trans-pellitorin, a chemical having a structure according to Formula (II): (II) Petition 870210111416, dated 01 / 12 / 2021, pages 68 / 104 63 / 83

[0195] The salivating agent may include sodium bicarbonate, sodium chloride, transpellitorin, pilocarpine, citrate, and combinations thereof. The salivating agents may be present from about 1% to about 60%, from about 1% to about 50%, or from about 1% to about 40% by weight of the oral treatment composition. Additionally, the salivating agents may be present from about 0.005% to about 10% by weight of the oral treatment composition, from about 0.01% to about 7% by weight of the oral treatment composition, or from about 0.015% to about 6% by weight of the oral treatment composition.

[0196] Salivating agents can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Thickening agent

[0197] The oral treatment compositions in the present invention may include one or more thickening agents. A thickening agent may be used in an amount of about 0.01% to about 15%, or about 0.1% to about 10%, or about 0.1% to about 5%, by weight of the oral treatment composition. Non-limiting examples may include those described in US 2008 / 0081023 A1, paragraphs 134 to 137, and the references cited therein.

[0198] The composition for oral treatment may comprise a linear sulfated polysaccharide as a thickening agent. Carrageenans are an example of a linear sulfated polysaccharide. In general, carrageenans may vary based on the degree of Petition 870210111416, dated 01 / 12 / 2021, pages 69 / 104 64 / 83 sulfation, which includes: kappa-carrageenan, iota-carrageenan and lambda-carrageenan. Combinations of carrageenans may be used. The mouthwash composition may contain from about 0.1% to about 3% of a linear sulfated polysaccharide by weight of the mouthwash composition, from about 0.5% to about 2%, from about 0.6% to about 1.8% or combinations thereof.

[0199] The oral treatment composition may comprise a silica agent, preferably a thickening silica obtained from sodium silicate solution by destabilizing it with acid to produce very fine particles. A commercially available example is the ZEODENT® brand silicas, available from Huber Engineered Materials (e.g., ZEODENT® 103, 124, 113, 115, 163, 165 and 167). The oral treatment composition may include from about 0.5% to about 5% by weight of a silica agent, preferably from about 1% to about 4%, alternatively from about 1.5% to about 3.5%, alternatively from about 2% to about 3%, alternatively from about 2% to about 5%, alternatively from about 1% to 3%, alternatively, combinations thereof.

[0200] The thickening agent may comprise carboxymethylcellulose (CMC). CMC is prepared from cellulose by treatment with alkali and monochloroacetic acid or its sodium salt. Different varieties are commercially characterized by viscosity. A commercially available example is Aqualon™ brand CMC available alongside Ashland Special Ingredients (by Petition 870210111416, dated 01 / 12 / 2021, pp. 70 / 104 65 / 83 example, Aqualon™ 7H3SF; Aqualon™ 9M3SF Aqualon™ TM9A; Aqualon™ TM12A). The thickening agent may contain from about 0.1% to about 3% of a CMC by weight of the oral treatment composition, preferably from about 0.5% to about 2%, alternatively from about 0.6% to about 1.8%, alternatively combinations thereof.

[0201] Thickening agents can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Chelating agents

[0202] The oral treatment compositions of the present invention may comprise one or more chelating agents. The term chelating agent, as used herein, means a bidentate or multidentate ligand having at least two groups capable of binding to metal ions and, preferably, to other divalent or polyvalent metal ions and which, at least as part of a mixture of chelating agents, is capable of solubilizing stannous ions or other optional metal ions in the oral treatment composition. The groups capable of binding to metal ions include carboxyl, hydroxyl and amine groups.

[0203] Suitable chelating agents of the present invention include C2-C6 dicarboxylic and tricarboxylic acids, such as succinic acid, malic acid, tartaric acid and citric acid; C3-C6 monocarboxylic acids substituted with hydroxyl, such as gluconic acid; picolinic acid; amino acids such as glycine; salts thereof and mixtures thereof. Chelating agents may also be a Petition 870210111416, dated 01 / 12 / 2021, pp. 71 / 104 66 / 83 polymer or copolymer in which the chelating ligands are on the same monomer or on the adjacent monomer.

[0204] Preferred chelating polymers are polyacids selected from the group consisting of a monomer homopolymer, a copolymer of two or more different monomers, and a combination thereof, wherein the monomer or at least one of the two or more different monomers is selected from the group consisting of acrylic acid, methacrylic acid, itaconic acid, maleic acid, glutaconic acid, aconitic acid, citraconic acid, mesaconic acid, fumaric acid, and tiglic acid. Particularly preferred is a methyl vinyl ether / maleic acid (PVM / MA) copolymer. Other useful chelators include polyphosphates, as discussed in this document.

[0205] The preferred organic acid chelators of the present invention comprise citrate, malate, tartrate, gluconate, succinate, lactate, malonate, maleate and mixtures thereof, whether added in their acid-free or salt forms.

[0206] The oral treatment compositions of the present invention may have low chelating agent contents because metal ions may require less stabilization if introduced into a fibrous composition, a non-fibrous composition, or physically separated from other reactive components of the oral treatment composition, which may be added in a separate mat layer or in the non-fibrous composition. The oral treatment composition may have less than about 5%, less than about 1%, less than about 0.5%, less than about 0.1%, less Petition 870210111416, dated 01 / 12 / 2021, pp. 72 / 104 67 / 83 that approximately 0.01%, or 0% of chelating agents, by weight of the oral treatment composition. The chelating agents may be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Bleaching agents

[0207] The oral treatment composition may additionally comprise from about 0.1% to about 10%, or from about 0.2% to about 5%, from about 1% to about 5%, or from about 1% to about 15%, by weight of the oral treatment composition of a bleaching agent. The bleaching agent may be a compound suitable for bleaching at least one tooth in the oral cavity. The bleaching agent may include peroxides, metallic chlorites, perborates, percarbonates, peroxyacids, persulfates, and combinations thereof. Suitable peroxides include solid peroxides, urea peroxide, calcium peroxide, benzoyl peroxide, sodium peroxide, barium peroxide, inorganic peroxides, hydroperoxides, organic peroxides, and mixtures thereof. Suitable metallic chlorites include calcium chlorite, barium chlorite, magnesium chlorite, lithium chlorite, sodium chlorite, and potassium chlorite.Other suitable bleaching agents include sodium persulfate, potassium persulfate, peroxidone, hexanoic acid 6-phthalimidoperoxy, phthalamidoperoxycaproic acid, or mixtures thereof.

[0208] Bleaching agents can be reactive with other components of oral treatment compositions; therefore, they can be separated from other components using the model assembly described in the present invention. Petition 870210111416, dated 01 / 12 / 2021, pp. 73 / 104 68 / 83 Bleaching agents can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Bioactive materials

[0209] The oral treatment composition may also include bioactive materials suitable for tooth remineralization. Suitable bioactive materials include bioactive glasses, Novamin™, Recaldent™, hydroxyapatite, amino acids such as arginine, citrulline, glycine, lysine, or histidine, or combinations thereof. Other suitable bioactive materials include any calcium phosphate compound. Other suitable bioactive materials include compounds comprising a calcium source and a phosphate source.

[0210] Bioactive glasses comprise calcium and / or phosphate which may be present in a proportion similar to hydroxyapatite. These glasses can bind to tissue and are biocompatible. Bioactive glasses may include a phosphopeptide, a calcium source, a phosphate source, a silica source, a sodium source, and / or combinations thereof.

[0211] The oral treatment composition may comprise from about 0.01% to about 20%, from about 0.1% to about 10%, or from about 1% to about 10% of a bioactive material by weight of the oral treatment composition.

[0212] Bioactive materials can be formed within the fibrous composition, added to the surface of the fibrous composition, or included in the non-fibrous composition. Petition 870210111416, dated 01 / 12 / 2021, pp. 74 / 104 69 / 83 Non-fibrous compositions

[0213] The components described herein may optionally be present, at least partially, as a non-fibrous composition. The non-fibrous composition may be between two or more layers of mat, folded into at least one layer of mat, rolled within at least one layer of mat, or wrapped around at least one layer of mat. At least a portion of the non-fibrous composition may come into contact with the surface of a fibrous composition. The non-fibrous composition may be liquid, solid, aqueous, and / or combinations thereof.

[0214] The non-fibrous composition may comprise an active ingredient for oral treatment, cosmetic agent, abrasive, fluoride ion source, mat-forming material, metal ion source, polyphosphate, chelating agent, anti-calculus agents, thickening agent, polymer, surfactant, bioactive material and / or combinations thereof.

[0215] The non-fibrous composition may be from about 10% to about 90%, from about 20% to about 85%, from about 30% to about 80%, from about 40% to about 75%, from about 50% to about 80%, from about 50% to about 90%, or from about 60% to about 80% by weight of the composition for oral treatment.

[0216] The density of the non-fibrous composition can be from about 0.05 g / cm3 to about 5 g / cm3, from about 0.75 g / cm3 to about 1.9 g / cm3, from about 1 g / cm3 to about 1.75 g / cm3 or from about 1.4 g / cm3 to about 1.8 g / cm3. Petition 870210111416, dated 01 / 12 / 2021, pp. 75 / 104 70 / 83 Coating composition

[0217] The components described herein may optionally be present, at least partially, as a coating composition. The coating composition may be applied to the fibrous composition, the mat, or the oral treatment composition. The coating composition at least partially covers or covers an external surface of the fibrous composition or the mat. The coating composition may cover an external surface of the oral treatment composition, positioning the coating composition to immediately come into contact with the target surface (e.g., saliva in the mouth) during use for the release of the oral treatment active(s) and / or aesthetic agent(s).

[0218] The coating composition of the present invention may comprise one or more oral treatment actives, as defined herein. The coating composition of the present invention may comprise one or more aesthetic agents as defined herein.

[0219] The fibrous composition, sheet, or oral treatment composition may comprise one or more oral treatment actives that may be the same as or different from the oral treatment active present in the coating composition. The fibrous composition, sheet, or oral treatment composition may comprise a delayed-release, extended-release oral treatment active and / or a targeted-release oral treatment active, and the coating composition comprises an immediate-release oral treatment active. A Petition 870210111416, dated 01 / 12 / 2021, pp. 76 / 104 71 / 83 fibrous composition, coating, or composition for oral treatment may comprise one or more aesthetic agents that may be the same as or different from the aesthetic agent in the coating composition.

[0220] The coating composition can also be trapped within the fibrous composition or mat. In this way, the particles of the coating composition can fit into the empty space between the fibers or filaments when formed into a mat using any suitable means. Removable components

[0221] Oral treatment actives, aesthetic agents, or other components in the oral treatment composition may be designed to be removable under a suitable firing condition. The removable components may be removable under the same or different firing conditions. For example, a flavoring capsule may be removable under a shear rate associated with a user brushing at least one tooth. A fluoride ion source may be removable upon contact with water. This may allow oral treatment actives or aesthetic agents to be released at a designated time. For example, a flavoring may be released 1 second after brushing while a colorant may be releaseable after a user brushes their teeth for two minutes to indicate that an adequate brushing time has passed.Cosmetic or active agents for oral treatment can be applied sequentially or simultaneously with other cosmetic or active agents for oral treatment. Petition 870210111416, dated 01 / 12 / 2021, pp. 77 / 104 72 / 83 Graphics

[0222] Graphics may be printed directly onto oral hygiene compositions. Suitable graphics include graphics to correlate with flavorings, graphics of sports team logos or names, graphics to correlate with directions for use, such as use at a specific time of day, after consuming a certain food or drink, or the type of brush to use, marketing material, colors, designs, logos, graphics depicting fictional and non-fictional characters, graphics linked to a consumer benefit, flags, slogans, catchphrases, motivational quotes, branding material, company information, ingredient lists, animals, or other graphics suitable for conveying information directly on the oral hygiene compositions. Graphics may be printed on each side of the oral hygiene composition. Graphics may be the same or different on each side of the oral hygiene composition. Dissolution time

[0223] The oral treatment compositions of the present invention can be described by their dissolution times. The oral treatment compositions of the present invention dissolve much faster than a comparable toothpaste. The oral treatment compositions comprising a fibrous composition of the present invention may have a total dissolution time according to the dissolution method as described herein, less than about 1000 seconds, less than about 750 seconds, less than about 500 seconds, less than Petition 870210111416, dated 01 / 12 / 2021, pp. 78 / 104 73 / 83 approximately 250 seconds, from approximately 50 seconds to approximately 250 seconds, or from approximately 50 seconds to approximately 500 seconds per dose of oral treatment composition. The foam compositions of the present invention may have a total dissolution time according to the dissolution method described herein of less than approximately 50 seconds, less than approximately 30 seconds, or less than approximately 20 seconds per dose of the foam composition. Comparable toothpaste formulations have dissolution times greater than 1000 seconds, which is not suitable for a unit-dose oral treatment composition that needs to dissolve upon contact with moisture in the oral cavity. Fluoride absorption

[0224] The oral treatment compositions, as described herein, can be described according to their average fluoride absorption by dissolving PAHs. The oral treatment compositions of the present invention have a higher average absorption F despite also comprising components that are typically avoided or carefully avoided due to reactivity with fluoride ions. For example, the oral treatment compositions may have an average fluoride absorption of at least 1000 ppm, at least 1500 ppm, or at least 2000 ppm despite comprising a fluoride ion source and a calcium ion source, which may react to form precipitated calcium fluoride before use by a consumer. The oral treatment compositions, as described herein, physically separate the fluoride ion source from the calcium ion source in layers of nonwoven mat. Petition 870210111416, dated 01 / 12 / 2021, pp. 79 / 104 74 / 83 different, in separate portions, in compositions separate from oral treatment compositions, or in a soluble solid phase. Physical separation of these components has been difficult to achieve previously. Unit-dose oral treatment compositions, such as containment bags, solid foams, or soluble fibrous compositions, provide the chassis that can physically separate fluoride ions from calcium ions during storage, but also allows them to be combinable after dissolution and / or disintegration in the oral cavity. Absorption of tin ions

[0225] The oral treatment compositions, as described herein, can be described according to their average absorption of tin ions by dissolving PAHs. The oral treatment compositions of the present invention have a higher average Sn absorption, despite also comprising components that are typically avoided or carefully formulated due to reactivity with tin ions. For example, the oral treatment compositions may have an average tin ion absorption of at least 5000 ppm, at least 10000 ppm, or at least 20000 ppm despite comprising a tin ion source and a polyphosphate, silica-based abrasive, etc., which may react to form tin complexes that decrease the availability of tin ions before use by a consumer.The oral treatment compositions, as described herein, physically separate the source of metal ions from polyphosphates, silica-based abrasives, or other chelating agents in layers of non-woven fabric. Petition 870210111416, dated 01 / 12 / 2021, pages 80 / 104 75 / 83 different, in separate portions, in compositions separate from the oral treatment compositions, or in a soluble solid phase. Physical separation of these components has been difficult to achieve previously. Unit-dose oral treatment compositions, such as containment bags, solid foams, or soluble fibrous compositions, provide the chassis that can physically separate metal ions from other reactive components during storage, but also allows them to be combinable after dissolution and / or disintegration in the oral cavity. Morphology

[0226] The oral treatment composition, as described herein, can be described by its morphology, which is unique in relation to other oral treatment compositions, such as toothpastes and / or mouthwashes. For example, a unit-dose oral treatment composition comprising a fibrous composition may be a nonwoven mat of fiber and / or filaments. A unit-dose oral treatment composition comprising a solid soluble foam composition may have voids within a solid foam network connected by struts. Solid soluble foam compositions may have an average void space volume percentage, or the ratio of void space to total space occupied by the foam, of at least about 75%, at least about 85%, or at least about 88%. In contrast, fibrous compositions may have an average void space volume of about 15% to about 75%, from about 15% to Petition 870210111416, dated 01 / 12 / 2021, pp. 81 / 104 76 / 83 approximately 70%, from approximately 30% to approximately 75%, or from approximately 35% to approximately 70%. Toothpastes and / or mouthwashes would have average empty space volume percentages of less than 15% before use by a consumer.

[0227] Solid soluble foam compositions may have an average pore size greater than about 0.1 mm, greater than about 0.2 mm, or greater than about 0.3 mm. In contrast, fibrous compositions may have an average pore size of about 0.001 mm to about 0.1 mm, about 0.01 mm to about 0.05 mm, or about 0.01 mm to about 0.1 mm. Toothpastes and / or mouthwashes are not expected to have pores until use by a consumer since they are liquids and / or pastes.

[0228] Soluble solid foam compositions may have a surface area of ​​about 50 mm-1 to about 150 mm-1, about 75 mm-1 to about 160 mm-1, or about 100 mm-1 to about 150 mm-1. In contrast, the surface area of ​​fibrous compositions may be at least about 150 mm-1, at least about 200 mm-1, or at least about 250 mm-1. Kits

[0229] As disclosed in this invention, a kit may comprise one or more single-dose oral treatment compositions. Single-dose oral treatment compositions may allow for a variety of novel kits, since each oral treatment composition may be supplied in a different unit dose of traditional toothpaste. Petition 870210111416, dated 01 / 12 / 2021, pp. 82 / 104 77 / 83

[0230] The kit may comprise two or more unit-dose oral treatment compositions, three or more unit-dose oral treatment compositions, four or more unit-dose oral treatment compositions, five or more unit-dose oral treatment compositions, six or more unit-dose oral treatment compositions, or seven or more unit-dose oral treatment compositions. Each unit-dose oral treatment composition may comprise one or more unique components, such as a flavoring, benefit agent, active oral treatment agent, and / or combinations thereof.

[0231] Thus, for example, a single kit may comprise a first unit-dose composition comprising a first flavoring and a second unit-dose oral treatment composition with a second flavoring. The first flavoring may be a mint flavoring and the second flavoring may be chewing gum. This may allow a single consumer to experience multiple flavorings with a single purchase of the kit, or more than one consumer, such as a parent and child, to experience different flavorings. Other examples of flavorings are described in the present invention.

[0232] The kit may also comprise more than one unit-dose oral treatment composition formulation. For example, the kit may comprise a first unit-dose oral treatment composition with a first beneficial agent and a second unit-dose oral treatment composition with a second beneficial agent. Petition 870210111416, dated 01 / 12 / 2021, pages 83 / 104 78 / 83 Benefit. The benefit agents may comprise one or more of the incompatible ingredients as described in the present invention. For example, the first benefit agent may comprise stannous fluoride and the second benefit agent may comprise hydrogen peroxide, such as the two-paste system described in U.S. Patent Application Publication No. 2016 / 0045408, which is incorporated herein by reference. The first benefit agent and the second benefit agent may be applied simultaneously, consecutively, or in different oral treatment sessions (i.e., one in the morning and one at night before bedtime).

[0233] Additionally, the first benefit agent may comprise an energy-boosting agent and the second benefit agent may comprise a sleep aid. Suitable energy-boosting agents may include caffeine, green and black tea, taurine, rhodiola rosea, Siberian ginseng (Eleutherococcus senticosus), CoQ10, L-carnitine, L-theanine, guarana (Paullinia cupana), Schizandra chinensis, yerba mate (Ilex paraguariensis), goji berry (Lycium barum and L. chinense), quercetin (a plant-derived flavonol), amalaki / Indian gooseberry (Phyllanthus emblica), açaí (from the genus Euterpe), maca (Lepidium meyenii), ginkgo biloba, glucuronolactone, panax ginseng (from the genus Panax, a genus of 11 species of slow-growing perennial plants with fleshy roots in the family Araliaceae), echinacea (a genus of nine species of herbaceous plants in the family Asteraceae), and rooibos. (Aspalathus linearis), DHEA, noni (Morinda citrifolia), mangosteen Petition 870210111416, dated 01 / 12 / 2021, pages 84 / 104 79 / 83 (Garcinia mangostana), and combinations thereof. Suitable sleep aids may include aolpidem, eszopiclone, zaleplon, doxepin, doxylamine, melatonin, ramelteon, estazolam, flurazepam hydrochloride, quazepam, temazepam, triazolam, and combinations thereof. Additionally, the first, second, third, etc. beneficial agents may comprise one of the active healthcare ingredients described in U.S. Patent No. 9,801,830, which is incorporated herein by reference. Oral treatment regimen

[0234] Also described in the present invention is an oral treatment regimen. The oral treatment regimen may comprise one or more oral treatment sessions comprising one or more unit-dose oral treatment compositions. Each oral treatment session may include the application of a single unit-dose oral treatment composition. Adding water to a toothbrush

[0235] The oral care composition may comprise wetting a toothbrush or other oral care implement for applying a composition to the oral cavity. Water may be added to the toothbrush by any suitable means, such as tap water, bottled water, mug water, natural spring water and / or combinations thereof. Collection of a single-dose oral hygiene composition for use with a toothbrush.

[0236] Residual water on the toothbrush may be sufficient for a mouthwash composition to adhere. Petition 870210111416, dated 01 / 12 / 2021, pages 85 / 104 80 / 83 of a unit dose is applied to the bristles of a toothbrush, as shown in Figure 1. The toothbrush can be inverted and the moistened bristles can be placed in contact with the unit dose oral treatment composition. Addition of water to the composition for single-dose oral treatment on the toothbrush.

[0237] After the unit-dose oral treatment composition is adhered to the toothbrush, additional amounts of water may optionally be added to the unit-dose oral treatment composition. As the unit-dose oral treatment composition comes into contact with water in the oral cavity or comes into contact with water on the toothbrush, the polymer in the unit-dose oral treatment composition may dissolve at least partially as shown in Figures 2, 3 and 4. Application of the unit-dose oral treatment composition to the oral cavity.

[0238] The unit dose compositions for oral treatment can then be applied to the oral cavity by brushing the surfaces of the oral cavity in an oral treatment session with the unit dose oral treatment composition for a period of up to 60 seconds, up to 120 seconds, up to 240 seconds, up to 300 seconds, from 1 second to about 60 seconds, from 1 second to about 120 seconds, from 1 second to about 240 seconds, or from 1 second to about 300 seconds. Petition 870210111416, dated 01 / 12 / 2021, pages 86 / 104 81 / 83 Additional oral treatment sessions

[0239] The oral treatment regimen may comprise a second, third, or more oral treatment sessions, which may be immediately after the first oral treatment session, or at a different time, such as at a different time within the same period or on a different day. The additional oral treatment session may include a single unit-dose oral treatment composition comprising a flavoring, benefit agent, single oral treatment active agent, etc., which is different from the unit-dose oral treatment composition of the first oral treatment session. Product for oral treatment

[0240] The present invention discloses an oral product comprising a box with a means for viewing the interior of the box and which may further comprise an insertable element, a container and / or one or more unit-dose oral treatment compositions, as described in the present invention.

[0241] The box, as seen in Figures 5 and 6, comprises a means for viewing the interior of the box before purchase. For example, the means may be a cutout, as shown in Figures 5 and 6, or it may be a transparent or translucent window made of a plastic material. The window may be the window as described in US Patent Application No. 16 / 254,636, which is incorporated herein by reference.

[0242] The insertable element can be sized to fit inside the box and hold a container in place inside the box. Petition 870210111416, dated 01 / 12 / 2021, pages 87 / 104 82 / 83

[0243] The container may be any container suitable for unit-dose oral treatment compositions. A suitable container may be a container described in U.S. Patent Application No. 16 / 411,175, which is incorporated herein by reference.

[0244] The oral treatment product may also include one or more unit-dose oral treatment compositions, as described in the present invention.

[0245] The oral treatment product may be designed and oriented so that the unit-dose oral treatment compositions can be visually inspected by the consumer who merely looks at the box. In this way, the consumer can see the unit doses through the box window.

[0246] Each document cited in the present invention, including any patent or patent application referenced or related, and any patent application or patent in which the present application claims priority or benefit thereof, is hereby incorporated in its entirety herein by reference, except where expressly excluded or otherwise limited. Reference to any document is not an admission that it constitutes prior art with respect to any invention disclosed or claimed herein, nor that it, by itself or in any combination with any other reference or references, teaches, suggests or discloses such invention. Furthermore, if there is a conflict between any meaning or definition of a term mentioned herein and any meaning or definition of the same term in a document incorporated by reference, it shall be considered as such. Petition 870210111416, dated 01 / 12 / 2021, pp. 88 / 104 83 / 83 precedes the meaning or definition assigned to this term in this document.

[0247] Although specific embodiments of the present invention have been illustrated and described, it will be evident to those skilled in the art that various other alterations and modifications can be made without departing from the spirit and scope of the invention. Therefore, it is intended to cover in the appended claims all such alterations and modifications that fall within the scope of the present invention. Petition 870210111416, dated 01 / 12 / 2021, pp. 89 / 104

Claims

1 / 3 CLAIMS 1. Kit characterized in that it comprises: (a) a first unit-dose oral treatment composition comprising: (i) a first flavoring; (ii) a first non-woven mat composition; and (iii) a first non-fibrous solid composition wrapped around the first non-woven mat composition, the first non-fibrous solid composition having a first color; and (b) a second unit-dose oral treatment composition comprising: (i) a second flavoring; (ii) a second non-woven mat composition; and (iii) a second non-fibrous solid composition wrapped around the second non-woven mat composition, the second non-fibrous solid composition having a second color different from the first color;wherein the first flavoring is not equivalent to the second flavoring, and the first unit-dose oral treatment composition and the second unit-dose oral treatment composition are used in different oral treatment sessions, and Petition 870250051412, dated 06 / 18 / 2025, page 6 / 17 2 / 3 wherein the first unit-dose oral treatment composition and the second unit-dose oral treatment composition can be collected by a wet toothbrush.

2. Kit according to claim 1, characterized in that the first nonwoven fabric composition and / or the second nonwoven fabric composition comprises at least one of: (a) one or more surfactants; (b) a polymer; (c) a metal ion source; (d) a fluoride ion source; and / or (e) a plasticizer.

3. Kit, according to claim 2, characterized in that the metal ion source comprises a tin ion source, a zinc ion source, or combinations thereof.

4. Kit according to claim 2, characterized in that the fluoride ion source comprises stannous fluoride, sodium fluoride, sodium monofluorophosphate, amine fluoride or combinations thereof.

5. Kit, according to claim 2, characterized in that the polymer comprises polyvinyl alcohol, starch or combinations thereof.

6. Kit, according to claim 1, characterized in that the kit comprises a third unit-dose oral treatment composition comprising a third flavoring, wherein the third flavoring is not equivalent to the first flavoring or the second flavoring.

Images